Gene Expression for Glutamic Acid Decarboxylase Is Re
Prefrontal Cortex of Schizophrenics

Archives of General Psychiatry

52, 258

DOI: 10.1001/archpsyc.1995.03950160008002

Citation Report

#	Article	IF	Citations
1	Reduced Inhibitory Capacity in Prefrontal Cortex of Schizophrenics. Archives of General Psychiatry, 1995, 52, 267.	13.8	12
2	The functional architecture of the prefrontal cortex and schizophrenia. Psychological Medicine, 1995, 25, 887-894.	2.7	73
3	Neural Circuitry of the Prefrontal Cortex in Schizophrenia. Archives of General Psychiatry, 1995, 52, 269.	13.8	32
4	Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Research, 1995, 699, 297-304.	1.1	177
5	Neocortical Abnormalities in Schizophrenia. Archives of General Psychiatry, 1995, 52, 819.	13.8	46
6	In Pursuit of the Molecular Neuropathology of Schizophrenia. Archives of General Psychiatry, 1995, 52, 274.	13.8	10
7	The NMDA Receptor as a Site for Psychopathology. Archives of General Psychiatry, 1995, 52, 1008.	13.8	12
8	Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity. Biological Psychiatry, 1995, 38, 783-787.	0.7	15
9	Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Research, 1995, 59, 81-96.	1.7	191
10	Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophrenia Research, 1996, 19, 111-119.	1.1	114
11	Neurobiology of treatment-resistant schizophrenia: new insights and new models. European Neuropsychopharmacology, 1996, 6, 27-34.	0.3	13
12	Differential distribution of Î³-aminobutyric acidA, receptor subunit (Î±1, Î±2, Î±3, Î±5 and Î²2+3) immunoreactivity in the medial prefrontal cortex of the rat. Neuroscience Letters, 1996, 210, 213-217.	1.0	18
13	Does the biology go around the symptoms? A copernican shift in schizophrenia paradigms. Clinical Psychology Review, 1996, 16, 641-654.	6.0	12
14	Maldistribution of Interstitial Neurons in Prefrontal White Matter of the Brains of Schizophrenic Patients. Archives of General Psychiatry, 1996, 53, 425.	13.8	365
15	Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience, 1996, 16, 19-30.	1.7	409
16	NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. Journal of Neuroscience, 1996, 16, 373-379.	1.7	406
17	Disordered functional connectivity in schizophrenia. Psychological Medicine, 1996, 26, 663-667.	2.7	187
18	Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathologica, 1996, 92, 217-231.	3.9	191

#	Article	IF	Citations
19	Local circuit neurons in the medial prefrontal cortex (areas 24a,b,c, 25 and 32) in the monkey: I. Cell morphology and morphometrics. Journal of Comparative Neurology, 1996, 364, 567-608.	0.9	161
20	Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. , 1996, 22, 338-349.		138
21	Retinoid Dysregulation May Result in Abnormal Expression of Glutamic Acid Decarboxylase in Schizophrenia. Archives of General Psychiatry, 1996, 53, 653.	13.8	33
22	The Glutamatergic Dysfunction Hypothesis for Schizophrenia. Harvard Review of Psychiatry, 1996, 3, 241-253.	0.9	526
24	Advances in post mortem molecular neurochemistry and neuropathology: examples from schizophrenia research. British Medical Bulletin, 1996, 52, 527-538.	2.7	26
25	Disrupted Pattern of D2 Dopamine Receptors in the Temporal Lobe in Schizophrenia. Archives of General Psychiatry, 1997, 54, 649.	13.8	67
26	Increased Concentrations of Presynaptic Proteins in the Cingulate Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 559.	13.8	126
27	Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. American Journal of Psychiatry, 1997, 154, 1013-1015.	4.0	189
28	Schizophrenia and Disordered Neural Circuitry. Schizophrenia Bulletin, 1997, 23, 529-531.	2.3	19
29	Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Journal of Psychopharmacology, 1997, 11, 3-12.	2.0	81
30	Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia. Journal of Psychopharmacology, 1997, 11, 133-142.	2.0	30
31	Postmortem Studies of the Hippocampal Formation in Schizophrenia. Schizophrenia Bulletin, 1997, 23, 385-402.	2.3	95
32	Neuropathology of Schizophrenia: Cortex, Thalamus, Basal Ganglia, and Neurotransmitter-specific Projection Systems. Schizophrenia Bulletin, 1997, 23, 403-421.	2.3	163
33	The role of serotonin in the pathophysiology and treatment of schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 1997, 9, 1-17.	0.9	197
34	Reduction of Synaptophysin Immunoreactivity in the Prefrontal Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 943.	13.8	268
35	SCHIZOPHRENIA, PSYCHOSIS, AND THE BASAL GANGLIA. Psychiatric Clinics of North America, 1997, 20, 897-910.	0.7	26
36	Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research, 1997, 24, 349-355.	1.1	343
37	Gene expression and neuronal activity in schizophrenia: a study of polyadenylated mRNA in the hippocampal formation and cerebral cortex. Schizophrenia Research, 1997, 26, 93-102.	1.1	22

#	Article	IF	Citations
38	Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology. Schizophrenia Research, 1997, 27, 169-180.	1.1	11
39	Neurobiology of schizophrenia. Current Opinion in Neurobiology, 1997, 7, 701-707.	2.0	147
40	Mesoprefrontal dopaminergic neurons: Can tyrosine availability influence their functions?. Biochemical Pharmacology, 1997, 53, 441-453.	2.0	62
41	Neuroimaging, Neurodevelopment, and Schizophrenia. Child and Adolescent Psychiatric Clinics of North America, 1997, 6, 325-342.	1.0	1
42	Localization of CAM II Kinase-Î±, GAD, GluR2 and GABAA Receptor Subunit mRNAs in the Human Entorhinal Cortex. European Journal of Neuroscience, 1997, 9, 662-675.	1.2	15
43	An emerging pathophysiology. Nature, 1997, 385, 578-579.	13.7	36
44	Development of the Prefrontal Cortex during Adolescence: Insights into Vulnerable Neural Circuits in Schizophrenia. Neuropsychopharmacology, 1997, 16, 385-398.	2.8	317
45	Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity. Neuropsychopharmacology, 1997, 17, 205-229.	2.8	296
46	Neuropathological studies of brain tissue in schizophrenia. Journal of Psychiatric Research, 1997, 31, 159-173.	1.5	24
47	Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Journal of Psychiatric Research, 1997, 31, 233-256.	1.5	69
48	A two-process theory of schizophrenia: Evidence from studies in post-mortem brain. Journal of Psychiatric Research, 1997, 31, 277-295.	1.5	67
49	The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. Journal of Psychiatric Research, 1997, 31, 257-275.	1.5	99
50	Reduction of Synaptophysin Immunoreactivity in the Prefrontal Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 660.	13.8	139
51	Initial development of ?-aminobutyric acid immunoreactivity in the human cerebral cortex. , 1997, 380, 495-506.		61
52	Chandelier cells: shedding light on altered cortical circuitry in schizophrenia. Molecular Psychiatry, 1998, 3, 468-471.	4.1	16
53	Genome scan of European-American schizophrenia pedigrees: Results of the NIMH genetics initiative and millennium consortium. , 1998, 81, 290-295.		253
54	Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. Journal of Comparative Neurology, 1998, 392, 402-412.	0.9	372
55	Synaptic changes in the striatum of schizophrenic cases: A controlled postmortem ultrastructural study. Synapse, 1998, 28, 125-139.	0.6	40

#	Article	IF	Citations
56	Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. , 1998, 29, 323-332.		93
57	Disinhibition of the mediodorsal thalamus induces Fos-like immunoreactivity in both pyramidal and GABA-containing neurons in the medial prefrontal cortex of rats, but does not affect prefrontal extracellular GABA levels. , 1998, 30, 156-165.		24
58	Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Molecular Brain Research, 1998, 53, 112-119.	2.5	66
59	GABA and brain abnormalities in schizophrenia. Psychiatry Research - Neuroimaging, 1998, 82, 25-35.	0.9	20
60	Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study. Biological Psychiatry, 1998, 43, 107-117.	0.7	48
61	Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biological Psychiatry, 1998, 44, 423-427.	0.7	43
62	A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biological Psychiatry, 1998, 44, 88-97.	0.7	441
63	BRAIN FUNCTIONS AND PSYCHIATRIC DISORDERS. Psychiatric Clinics of North America, 1998, 21, 517-566.	0.7	17
64	THE NEUROANATOMY AND NEUROCHEMISTRY OF SCHIZOPHRENIA. Psychiatric Clinics of North America, 1998, 21, 57-75.	0.7	25
65	CSF N-CAM in neuroleptic-naÄ±Ì^ve first-episode patients with schizophrenia. Schizophrenia Research, 1998, 34, 123-131.	1.1	26
66	NEURODEVELOPMENTAL AND NEUROPROGRESSIVE PROCESSES IN SCHIZOPHRENIA. Psychiatric Clinics of North America, 1998, 21, 123-149.	0.7	48
67	A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15718-15723.	3.3	714
68	Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures. Cerebral Cortex, 1998, 8, 614-622.	1.6	116
69	Schizophrenia, Sensory Gating, and Nicotinic Receptors. Schizophrenia Bulletin, 1998, 24, 189-202.	2.3	653
70	A subclass of prefrontal Â-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5341-5346.	3.3	402
71	A Candidate Molecule Approach to Defining Developmental Pathology in Schizophrenia. Schizophrenia Bulletin, 1998, 24, 303-316.	2.3	72
72	"Cognitive Dysmetria" as an Integrative Theory of Schizophrenia: A Dysfunction in Cortical-Subcortical-Cerebellar Circuitry?. Schizophrenia Bulletin, 1998, 24, 203-218.	2.3	1,068
73	Altered ratios of alternatively spliced long and short Â2 subunit mRNAs of the Â-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15066-15071.	3.3	129

#	Article	IF	Citations
74	Dopamine Modulation of Membrane and Synaptic Properties of Interneurons in Rat Cerebral Cortex. Journal of Neurophysiology, 1999, 81, 967-976.	0.9	169
75	Panmodal Processing Imprecision as a Basis for Dysfunction of Transient Memory Storage Systems in Schizophrenia. Schizophrenia Bulletin, 1999, 25, 763-775.	2.3	89
76	â– REVIEW : Long-Term Modulation of Gene Expression in Epilepsy. Neuroscientist, 1999, 5, 86-99.	2.6	24
77	Cortical bitufted, horizontal, and Martinotti cells preferentially express and secrete reelin into perineuronal nets, nonsynaptically modulating gene expression. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3217-3222.	3.3	148
78	Alcoholic Typology and Season of Birth. Journal of Addictive Diseases, 1999, 18, 41-52.	0.8	12
79	Differential Origins of Neocortical Projection and Local Circuit Neurons: Role of Dlx Genes in Neocortical Interneuronogenesis. Cerebral Cortex, 1999, 9, 646-654.	1.6	301
80	Mechanisms underlying epileptogenesis in cortical malformations. Epilepsy Research, 1999, 36, 165-188.	0.8	154
81	Epilepsy, Schizophrenia, and the Extended Amygdala. Annals of the New York Academy of Sciences, 1999, 877, 548-561.	1.8	33
82	Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for â€˜hypofrontalityâ€™. Molecular Psychiatry, 1999, 4, 39-45.	4.1	207
83	Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psychopharmacology, 1999, 144, 347-354.	1.5	78
84	Cognition and neuropathology in schizophrenia. Acta Psychiatrica Scandinavica, 1999, 99, 41-50.	2.2	24
85	The Neuropsychopharmacology of Phencyclidine From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia. Neuropsychopharmacology, 1999, 20, 201-225.	2.8	1,160
86	No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia. Neuropsychopharmacology, 1999, 20, 650-661.	2.8	52
87	Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex. Neuropsychopharmacology, 1999, 21, 161-194.	2.8	163
88	Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists. Neuropsychopharmacology, 1999, 21, S143-S157.	2.8	59
89	The neuropathology of schizophrenia. Brain, 1999, 122, 593-624.	3.7	1,538
90	[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research - Neuroimaging, 1999, 91, 163-173.	0.9	45
91	Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor Î±-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression. Neuroscience, 1999, 93, 441-448.	1.1	142

#	Article	IF	Citations
92	GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Research Bulletin, 1999, 48, 467-473.	1.4	87
93	An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews, 1999, 29, 250-264.	9.1	156
94	Localization of cells preferentially expressing GAD67 with negligible GAD65 transcripts in the rat hippocampus. A double in situ hybridization study. Molecular Brain Research, 1999, 71, 201-209.	2.5	42
96	The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biological Psychiatry, 1999, 45, 17-25.	0.7	881
97	Forebrain induction, retinoic acid, and vulnerability to schizophrenia: insights from molecular and genetic analysis in developing mice. Biological Psychiatry, 1999, 46, 19-30.	0.7	101
98	Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biological Psychiatry, 1999, 46, 616-626.	0.7	252
99	Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biological Psychiatry, 1999, 46, 589-599.	0.7	166
100	Frontal Lobe Psychopathology: Mania, Depression, Confabulation, Catatonia, Perseveration, Obsessive Compulsions, and Schizophrenia. Psychiatry (New York), 1999, 62, 138-172.	0.3	116
101	Dopamine innervation of monkey entorhinal cortex: Postsynaptic targets of tyrosine hydroxylase-immunoreactive terminals. , 2000, 36, 47-56.		22
102	Differential expression of GABAA receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. Synapse, 2000, 38, 51-60.	0.6	16
103	Effects of cocaine administration on receptor binding and subunits mRNA of GABAA-benzodiazepine receptor complexes. Synapse, 2000, 38, 198-215.	0.6	31
104	Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry, 2000, 5, 293-300.	4.1	323
105	Cytokine and growth factor involvement in schizophreniaâ€"support for the developmental model. Molecular Psychiatry, 2000, 5, 594-603.	4.1	183
106	Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Molecular Psychiatry, 2000, 5, 654-663.	4.1	376
107	Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. British Journal of Pharmacology, 2000, 130, 33-40.	2.7	34
108	To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test. Neuropsychopharmacology, 2000, 23, 223-239.	2.8	567
109	New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochemical Research, 2000, 25, 1207-1218.	1.6	39
110	Colocalization of integrin receptors and reelin in dendritic spine postsynaptic densities of adult nonhuman primate cortex. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3550-3555.	3.3	149

#	Article	IF	Citations
111	Imidazenil prevention of alprazolam-induced acquisition deficit in patas monkeys is devoid of tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2314-2319.	3.3	20
112	Evidence of fronto-thalamic involvement in schizophrenia. Progress in Brain Research, 2000, 126, 343-355.	0.9	2
113	Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia. Archives of General Psychiatry, 2000, 57, 65.	13.8	1,419
114	Decrease in Reelin and Glutamic Acid Decarboxylase67 (GAD67) Expression in Schizophrenia and Bipolar Disorder. Archives of General Psychiatry, 2000, 57, 1061.	13.8	1,122
115	Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9276-9280.	3.3	258
116	Signal Transmission, Rather Than Reception, is the Underlying Neurochemical Abnormality in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2000, 34, 560-569.	1.3	49
117	Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical Î³-Aminobutyric Acid Neurons in Subjects With Schizophrenia. Archives of General Psychiatry, 2000, 57, 237.	13.8	622
118	Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates. Neuroscientist, 2000, 6, 263-270.	2.6	5
119	Is There a Neuropathology of Schizophrenia? Recent Findings Converge on Altered Thalamic-Prefrontal Cortical Connectivity. Neuroscientist, 2000, 6, 208-218.	2.6	47
120	Transduction of Human GAD67 cDNA into Immortalized Striatal Cell Lines Using an Epsteinâ€“Barr Virus-Based Plasmid Vector Increases GABA Content. Experimental Neurology, 2000, 161, 453-461.	2.0	21
121	Specific Frequencies of Spontaneous Ca2+ Transients Upregulate GAD 67 Transcripts in Embryonic Spinal Neurons. Molecular and Cellular Neurosciences, 2000, 16, 376-387.	1.0	66
122	Olanzapine increases allopregnanolone in the rat cerebral cortex. Biological Psychiatry, 2000, 47, 1000-1004.	0.7	103
123	Quantitative changes in reduced nicotinamide adenine dinucleotide phosphate-diaphorase-reactive neurons in the brain of Octodon degus after periodic maternal separation and early social isolation. Neuroscience, 2000, 99, 381-387.	1.1	16
124	Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Research Bulletin, 2000, 52, 309-317.	1.4	121
125	Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Research Reviews, 2000, 31, 138-146.	9.1	201
126	GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Research Reviews, 2000, 31, 270-276.	9.1	259
127	The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Research Reviews, 2000, 31, 371-384.	9.1	300
128	Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizophrenics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 241-249.	2.5	23

#	Article	IF	Citations
129	Immunohistochemical localization of Î³-aminobutyric acidB receptor in the hippocampus of subjects with schizophrenia. Neuroscience Letters, 2000, 283, 101-104.	1.0	59
130	Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance. Medical Hypotheses, 2000, 55, 314-318.	0.8	20
131	Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex. Neuron, 2000, 28, 53-67.	3.8	861
132	Catching Up on Schizophrenia. Neuron, 2000, 28, 325-334.	3.8	712
133	Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biological Psychiatry, 2000, 47, 944-953.	0.7	273
135	Normal cellular levels of synaptophysin mRNA expression in the prefrontal cortex of subjects with schizophrenia. Biological Psychiatry, 2000, 48, 389-397.	0.7	64
136	The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biological Psychiatry, 2001, 50, 395-406.	0.7	318
137	Dendritic Spine Hypoplasticity and Downregulation of Reelin and GABAergic Tone in Schizophrenia Vulnerability. Neurobiology of Disease, 2001, 8, 723-742.	2.1	188
138	Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Research Bulletin, 2001, 55, 651-659.	1.4	118
139	Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Research Bulletin, 2001, 55, 641-650.	1.4	236
140	Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Research Bulletin, 2001, 55, 579-584.	1.4	136
141	The visual backward masking deficit in Schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 301-311.	2.5	37
142	Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Progress in Neurobiology, 2001, 63, 241-320.	2.8	406
143	Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends in Neurosciences, 2001, 24, 479-486.	4.2	383
144	GABAergic neuronal subtypes in the human frontal cortex â€" development and deficits in schizophrenia. Journal of Chemical Neuroanatomy, 2001, 22, 95-100.	1.0	147
145	Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex. Neuropharmacology, 2001, 40, 366-382.	2.0	44
146	CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics of North America, 2001, 85, 559-577.	1.1	30
147	SCHIZOPHRENIA. Medical Clinics of North America, 2001, 85, 663-689.	1.1	18

#	Article	IF	Citations
148	A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications. Clinical Neuropharmacology, 2001, 24, 43-49.	0.2	135
149	Neural Development, Cell-Cell Signaling, and the "Two-Hit" Hypothesis of Schizophrenia. Schizophrenia Bulletin, 2001, 27, 457-476.	2.3	323
150	Lamina-Specific Deficits in Parvalbumin-Immunoreactive Varicosities in the Prefrontal Cortex of Subjects With Schizophrenia: Evidence for Fewer Projections From the Thalamus. American Journal of Psychiatry, 2001, 158, 1411-1422.	4.0	187
151	Regionally Diverse Cortical Pathology in Schizophrenia: Clues to the Etiology of the Disease. Schizophrenia Bulletin, 2001, 27, 349-377.	2.3	78
152	Amygdalar activation alters the hippocampal GABA system: ?Partial? modelling for postmortem changes in schizophrenia. Journal of Comparative Neurology, 2001, 431, 129-138.	0.9	90
153	Effects of pre- and postnatal corticosterone exposure on the rat hippocampal GABA system. Hippocampus, 2001, 11, 492-507.	0.9	55
154	Expression of AMPA Receptor Flip and Flop mRNAs in the Nucleus Accumbens and Prefrontal Cortex after Neonatal Ventral Hippocampal Lesions. Neuropsychopharmacology, 2001, 24, 253-266.	2.8	22
155	GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2001, 25, 1-27.	2.8	972
156	Clozapine, but not Haloperidol, Increases Brain Concentrations of Neuroactive Steroids in the Rat. Neuropsychopharmacology, 2001, 25, 489-497.	2.8	98
157	GABA Transporter-1 mRNA in the Prefrontal Cortex in Schizophrenia: Decreased Expression in a Subset of Neurons. American Journal of Psychiatry, 2001, 158, 256-265.	4.0	202
158	Association between GABA-A Receptor Alpha 5 Subunit Gene Locus and Schizophrenia of a Later Age of Onset. Neuropsychobiology, 2001, 43, 141-144.	0.9	15
159	Mesoprefrontal Dopamine Neurons and Schizophrenia: Role of Developmental Abnormalities. Schizophrenia Bulletin, 2001, 27, 431-442.	2.3	49
160	Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3477-3482.	3.3	211
161	Reduced Glial Cell Density and Neuronal Size in the Anterior Cingulate Cortex in Major Depressive Disorder. Archives of General Psychiatry, 2001, 58, 545.	13.8	701
162	Reduced GAP-43 mRNA in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia. Cerebral Cortex, 2001, 11, 136-147.	1.6	58
163	An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 17095-17100.	3.3	356
164	Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia. Archives of General Psychiatry, 2002, 59, 705.	13.8	157
165	Benzodiazepines in Schizophrenia: Prefrontal Cortex Atrophy Predicts Clinical Response to Alprazolam Augmentation. World Journal of Biological Psychiatry, 2002, 3, 221-224.	1.3	7

#	Article	IF	Citations
166	Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. Molecular Psychiatry, 2002, 7, 392-404.	4.1	91
167	The GABAergic system in schizophrenia. International Journal of Neuropsychopharmacology, 2002, 5, 159-79.	1.0	121
168	Differential Hippocampal Expression of Glutamic Acid Decarboxylase 65 and 67 Messenger RNA in Bipolar Disorder and Schizophrenia. Archives of General Psychiatry, 2002, 59, 521.	13.8	311
169	Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia. Cerebral Cortex, 2002, 12, 1063-1070.	1.6	244
170	Reduced Neuronal Size and Glial Cell Density in Area 9 of the Dorsolateral Prefrontal Cortex in Subjects with Major Depressive Disorder. Cerebral Cortex, 2002, 12, 386-394.	1.6	527
171	Mechanisms of Dopamine Activation of Fast-Spiking Interneurons That Exert Inhibition in Rat Prefrontal Cortex. Journal of Neurophysiology, 2002, 88, 3150-3166.	0.9	279
172	Decreased prefrontal CaMKII Î± mRNA in bipolar illness. NeuroReport, 2002, 13, 501-505.	0.6	60
173	Implications for Altered Glutamate and GABA Metabolism in the Dorsolateral Prefrontal Cortex of Aged Schizophrenic Patients. American Journal of Psychiatry, 2002, 159, 1165-1173.	4.0	97
174	Review of Antipsychotic Medication Administration: A Proposal of Intermittent Dosing. Schizophrenia Bulletin, 2002, 28, 203-222.	2.3	20
175	The density and spatial distribution of gabaergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biological Psychiatry, 2002, 51, 377-386.	0.7	209
176	Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry, 2002, 52, 708-715.	0.7	348
177	Schizophrenia: Diverse Approaches to a Complex Disease. Science, 2002, 296, 692-695.	6.0	549
178	Functional genomics in neuropsychiatric disorders and in neuropharmacology. Expert Opinion on Therapeutic Targets, 2002, 6, 363-374.	1.5	3
179	Development of the human cerebral cortex: A histochemical study. Progress in Histochemistry and Cytochemistry, 2002, 38, 3-49.	5.1	16
180	Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiology and Behavior, 2002, 77, 501-505.	1.0	149
181	The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Current Opinion in Pharmacology, 2002, 2, 56-62.	1.7	94
182	Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and schizophrenic. Thalamus & Related Systems, 2002, 1, 349-369.	0.5	8
183	Schizophrenia: A Critical Examination. , 2002, , 403-441.		3

#	Article	IF	Citations
184	Aminergic Transmitter Systems. , 0, , 581-586.		0
185	The Human Brain Revisited Opportunities and Challenges in Postmortem Studies of Psychiatric Disorders. Neuropsychopharmacology, 2002, 26, 143-154.	2.8	174
186	Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. Journal of Neural Transmission, 2002, 109, 881-889.	1.4	80
187	Hippocampal neurons in schizophrenia. Journal of Neural Transmission, 2002, 109, 891-905.	1.4	214
188	Reelin in the extracellular matrix and dendritic spines of the cortex and hippocampus: a comparison between wild type and heterozygous reeler mice by immunoelectron microscopy. Journal of Neurocytology, 2002, 30, 413-425.	1.6	79
189	A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus. Neurotoxicity Research, 2002, 4, 469-475.	1.3	134
190	Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia. Neurotoxicity Research, 2002, 4, 437-451.	1.3	5
191	NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology, 2003, 169, 215-233.	1.5	477
192	GAD67: the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. Journal of Neural Transmission, 2003, 110, 803-812.	1.4	54
193	Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Research - Neuroimaging, 2003, 124, 163-175.	0.9	34
194	The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems. Clinical Neuroscience Research, 2003, 3, 77-107.	0.8	41
195	Glycogen synthase kinase (GSK)-3Î² levels and activity in a neurodevelopmental rat model of schizophrenia. Developmental Brain Research, 2003, 141, 33-37.	2.1	31
196	Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex. Journal of Comparative Neurology, 2003, 465, 385-400.	0.9	110
197	GABA, ?-hydroxybutyric acid, and neurological disease. Annals of Neurology, 2003, 54, S3-S12.	2.8	419
198	Schizophrenia: from phenomenology to neurobiology. Neuroscience and Biobehavioral Reviews, 2003, 27, 269-306.	2.9	232
199	Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. European Journal of Neuroscience, 2003, 18, 391-402.	1.2	101
200	MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. Biological Psychiatry, 2003, 53, 39-47.	0.7	53
201	Effects of a mediodorsal thalamus lesion on prefrontal inhibitory circuitry: implications for schizophrenia. Biological Psychiatry, 2003, 53, 385-389.	0.7	23

#	Article	IF	Citations
202	Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biological Psychiatry, 2003, 54, 1212-1221.	0.7	39
203	Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biological Psychiatry, 2003, 53, 1075-1085.	0.7	393
204	Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 801-807.	2.5	93
205	Genetics of human prefrontal function. Brain Research Reviews, 2003, 43, 134-163.	9.1	124
206	Emerging Complexity of Layer I in Human Cerebral Cortex. Cerebral Cortex, 2003, 13, 1072-1083.	1.6	134
207	Microarray Technology: A Review of New Strategies to Discover Candidate Vulnerability Genes in Psychiatric Disorders. American Journal of Psychiatry, 2003, 160, 657-666.	4.0	134
208	White Matter Changes in Schizophrenia. Archives of General Psychiatry, 2003, 60, 443.	13.8	761
209	Decreased Thalamic Expression of the Homeobox Gene DLX1 in Psychosis. Archives of General Psychiatry, 2003, 60, 869.	13.8	18
210	Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents. Neuropsychopharmacology, 2003, 28, 1-13.	2.8	132
211	Cellular Pathology in the Dorsolateral Prefrontal Cortex Distinguishes Schizophrenia from Bipolar Disorder. Current Molecular Medicine, 2003, 3, 427-436.	0.6	60
213	Cortical pathology in schizophrenia: a review of data from the dorsolateral prefrontal cortex. Current Opinion in Psychiatry, 2003, 16, S9-S14.	3.1	0
214	Schizophrenia: Neural Mechanisms for Novel Therapies. Molecular Medicine, 2003, 9, 3-9.	1.9	50
215	Interactions of the Dopamine, Serotonin, and GABA Systems During Childhood and Adolescence: Influence of Stress on the Vulnerability for Psychopathology. , 2003, , 384-402.		0
217	Brain development: the clinical perspective. , 2003, , 74-92.		0
218	Perinatal Neurosteroid Levels Influence GABAergic Interneuron Localization in Adult Rat Prefrontal Cortex. Journal of Neuroscience, 2003, 23, 1832-1839.	1.7	68
219	Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia. Journal of Neuroscience, 2003, 23, 6315-6326.	1.7	843
220	Dopamine Modulates Cell Cycle in the Lateral Ganglionic Eminence. Journal of Neuroscience, 2003, 23, 2840-2850.	1.7	172
222	Neurochemical Basis for an Epigenetic Vision of Synaptic Organization. International Review of Neurobiology, 2004, 59, 73-91.	0.9	8

#	Article	IF	Citations
223	Possible Contributions of Myelin and Oligodendrocyte Dysfunction to Schizophrenia. International Review of Neurobiology, 2004, 59, 381-424.	0.9	51
224	Prepulse Inhibition Deficits in GAD65 Knockout Mice and the Effect of Antipsychotic Treatment. Neuropsychopharmacology, 2004, 29, 1610-1619.	2.8	59
225	The Neurotensin Agonist PD149163 Increases Fos Expression in the Prefrontal Cortex of the Rat. Neuropsychopharmacology, 2004, 29, 1878-1888.	2.8	43
226	Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression. Pharmacopsychiatry, 2004, 37, 171-174.	1.7	74
227	DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 348-353.	3.3	285
228	Association between prenatal exposure to analgesics and risk of schizophrenia. British Journal of Psychiatry, 2004, 185, 366-371.	1.7	36
229	Reply: Valproate Treatment in Schizophrenia: Interaction of GABA with Dopamine?. Neuropsychopharmacology, 2004, 29, 1218-1220.	2.8	1
230	Role of Neuroactive Steroid Allopregnanolone in Antipsychotic-like Action of Olanzapine in Rodents. Neuropsychopharmacology, 2004, 29, 1597-1609.	2.8	46
231	Influence of the hippocampus on interneurons of the rat prefrontal cortex. European Journal of Neuroscience, 2004, 20, 514-524.	1.2	173
232	The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochemical Pharmacology, 2004, 68, 1507-1514.	2.0	172
233	Reduced GSK-3? mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. Journal of Neural Transmission, 2004, 111, 1583-1592.	1.4	86
234	Gene-environment interplay in schizopsychotic disorders. Neurotoxicity Research, 2004, 6, 1-9.	1.3	21
235	Calcium binding protein markers of GABA deficits in schizophrenia â€" post mortem studies and animal models. Neurotoxicity Research, 2004, 6, 57-61.	1.3	145
236	Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology, 2004, 174, 143-50.	1.5	224
237	GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. Journal of Neuroscience Research, 2004, 76, 581-592.	1.3	95
238	Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophrenia Research, 2004, 66, 151-157.	1.1	57
239	Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. Biological Psychiatry, 2004, 55, 131-140.	0.7	73
240	Neuroplasticity and schizophrenia. Biological Psychiatry, 2004, 56, 540-543.	0.7	46

#	Article	IF	Citations
241	Repetitive transcranial magnetic stimulation reveals abnormal plastic response to premotor cortex stimulation in schizophrenia. Biological Psychiatry, 2004, 56, 628-633.	0.7	73
242	Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Research, 2004, 69, 237-253.	1.1	152
243	Plasticity of interneuronal species diversity and parameter variance in neurological diseases. Trends in Neurosciences, 2004, 27, 504-510.	4.2	38
244	Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 273-278.	2.5	63
245	Distribution of neuropeptide Y interneurons in the dorsal prefrontal cortex of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 379-383.	2.5	44
246	Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation. Neuropharmacology, 2004, 46, 1070-1081.	2.0	59
247	Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiology of Disease, 2004, 16, 220-235.	2.1	26
248	The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature Medicine, 2004, 10, 685-692.	15.2	416
249	Long-Term Treatment With Clozapine Does Not Affect Morning Circulating Levels of Allopregnanolone and THDOC in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 437-440.	0.7	9
250	Density of Glutamic Acid Decarboxylase 67 Messenger RNAâ€“ContainingNeurons That Express the N-Methyl-D-AspartateReceptor Subunit NR2A in the Anterior Cingulate Cortex in Schizophreniaand Bipolar Disorder. Archives of General Psychiatry, 2004, 61, 649.	13.8	382
251	Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. Psychiatric Genetics, 2004, 14, 39-42.	0.6	21
252	A Linkage Study Between the GABAA Î²2 and GABAAÎ³2 Subunit Genes and Major Psychoses. CNS Spectrums, 2005, 10, 57-61.	0.7	4
253	Altered Expression of 14-3-3 Genes in the Prefrontal Cortex of Subjects with Schizophrenia. Neuropsychopharmacology, 2005, 30, 974-983.	2.8	75
254	INVESTIGATING THE NEURODEVELOPMENTAL HYPOTHESIS OF SCHIZOPHRENIA. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 687-696.	0.9	65
255	Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience, 2005, 6, 312-324.	4.9	2,065
256	Phenotype of schizophrenia: a review and formulation. Molecular Psychiatry, 2005, 10, 27-39.	4.1	251
257	GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Molecular Psychiatry, 2005, 10, 581-588.	4.1	186
258	The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 2005, 10, 434-449.	4.1	864

#	Article	IF	Citations
259	Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Molecular Psychiatry, 2005, 10, 637-650.	4.1	222
260	Homeostatic activity-dependent paradigm for neurotransmitter specification. Cell Calcium, 2005, 37, 417-423.	1.1	34
261	Gene expression changes in schizophrenia: how do they arise and what do they mean?. Clinical Neuroscience Research, 2005, 5, 15-21.	0.8	3
262	Dorsolateral prefrontal cortex contribution to abnormalities of the P300 component of the event-related potential in schizophrenia. Psychiatry Research - Neuroimaging, 2005, 140, 17-26.	0.9	24
263	Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity. Journal of Psychiatric Research, 2005, 39, 117-127.	1.5	49
264	Contributions of cortical subventricular zone to the development of the human cerebral cortex. Journal of Comparative Neurology, 2005, 491, 109-122.	0.9	246
265	Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia. , 2005, 135B, 94-101.		44
266	GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology, 2005, 180, 191-205.	1.5	237
267	The Role of Altered Energetics of Neurotransmitter Systems in Psychiatric Disease. , 2005, , 239-256.		0
268	GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Current Neuropharmacology, 2005, 3, 45-62.	1.4	33
269	Reelin promoter hypermethylation in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9341-9346.	3.3	515
270	Neurotensin Activates GABAergic Interneurons in the Prefrontal Cortex. Journal of Neuroscience, 2005, 25, 1629-1636.	1.7	48
271	Neural Cell Adhesion Molecule-Secreting Transgenic Mice Display Abnormalities in GABAergic Interneurons and Alterations in Behavior. Journal of Neuroscience, 2005, 25, 4659-4671.	1.7	120
272	Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia. Journal of Neuroscience, 2005, 25, 372-383.	1.7	390
273	Chromatin Alterations Associated With Down-regulated Metabolic Gene Expression in the Prefrontal Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 2005, 62, 829.	13.8	124
274	Low GSK-3Î² in schizophrenia as a consequence of neurodevelopmental insult. European Neuropsychopharmacology, 2005, 15, 1-11.	0.3	38
275	An association study between polymorphisms in five genes in glutamate and GABA pathway and paranoid schizophrenia. European Psychiatry, 2005, 20, 45-49.	0.1	22
276	DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1749-1754.	3.3	124

#	Article	IF	Citations
277	In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2152-2157.	3.3	249
278	Positive association of the human GABA-A-receptor beta 2 subunit gene haplotype with schizophrenia in the Chinese Han population. Biochemical and Biophysical Research Communications, 2005, 334, 817-823.	1.0	26
279	Apoptotic mechanisms in the pathophysiology of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 846-858.	2.5	171
280	Lighting the chandelier: new vistas for axo-axonic cells. Trends in Neurosciences, 2005, 28, 310-316.	4.2	152
281	Neonatal lesions of the ventral hippocampal formation alter GABA-A receptor subunit mRNA expression in adult rat frontal pole. Biological Psychiatry, 2005, 57, 49-55.	0.7	13
282	Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biological Psychiatry, 2005, 57, 252-260.	0.7	408
283	Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biological Psychiatry, 2005, 57, 500-509.	0.7	243
284	GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophrenia Research, 2005, 72, 109-122.	1.1	271
285	Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophrenia Research, 2005, 73, 159-172.	1.1	171
286	Targeting synapses and myelin in the prevention of schizophrenia. Schizophrenia Research, 2005, 73, 193-207.	1.1	78
287	A cross-study meta-analysis and three-dimensional comparison of cell counting in the anterior cingulate cortex of schizophrenic and bipolar brain. Schizophrenia Research, 2005, 73, 79-89.	1.1	108
288	A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons. Journal of Neuroscience, 2006, 26, 1604-1615.	1.7	298
289	The Serotonin Receptors. Receptors, 2006, , .	0.2	27
290	Cognitive Dysfunction in Schizophrenia. Archives of Neurology, 2006, 63, 1372.	4.9	380
291	From The Cover: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1587-1592.	3.3	210
292	Critical Appraisal of DNA Microarrays in Psychiatric Genomics. Biological Psychiatry, 2006, 60, 163-176.	0.7	129
293	GABAA-receptor mRNA expression in the prefrontal and temporal cortex of ALS patients. Journal of the Neurological Sciences, 2006, 250, 124-132.	0.3	28
294	Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research, 2006, 81, 47-63.	1.1	273

#	Article	IF	Citations
295	Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophrenia Research, 2006, 84, 253-271.	1.1	119
296	The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research, 2006, 169, 263-273.	1.2	128
297	Schizophrenia: A unique translational opportunity in behavioral neuroendocrinology. Hormones and Behavior, 2006, 50, 602-611.	1.0	24
298	Regional specificity of chandelier neuron axon terminal alterations in schizophrenia. Neuroscience, 2006, 138, 189-196.	1.1	42
299	Typical and atypical antipsychotic drugs target dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa and neurotensin-containing neurons, but not GABAergic interneurons in the shell of nucleus accumbens of ventral striatum. Neuroscience, 2006, 141, 1469-1480.	1.1	6
300	Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. British Journal of Psychiatry, 2006, 188, 26-31.	1.7	93
301	Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine, 2006, 12, 1016-1022.	15.2	307
302	A rat model for neural circuitry abnormalities in schizophrenia. Nature Protocols, 2006, 1, 833-839.	5.5	13
303	Analysis of GABRB2 association with schizophrenia in German population with DNA sequencing and one-label extension method for SNP genotyping. Clinical Biochemistry, 2006, 39, 210-218.	0.8	30
304	Reelin down-regulation in mice and psychosis endophenotypes. Neuroscience and Biobehavioral Reviews, 2006, 30, 1065-1077.	2.9	90
305	Possible Mechanisms of Neurodegeneration in Schizophrenia. Neurochemical Research, 2006, 31, 1279-1294.	1.6	85
306	Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. Experimental Brain Research, 2006, 173, 234-242.	0.7	22
307	Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Research Reviews, 2006, 52, 293-304.	9.1	336
308	Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. Neurobiology of Disease, 2006, 22, 624-637.	2.1	87
309	BDNF Val66Met Polymorphism and GAD67mRNA Expression in the Prefrontal Cortex of Subjects With Schizophrenia. American Journal of Psychiatry, 2006, 163, 534-537.	4.0	33
310	Neonatal Ventral Hippocampal Lesions Produce an Elevation of Î”FosB-Like Protein(s) in the Rodent Neocortex. Neuropsychopharmacology, 2006, 31, 700-711.	2.8	19
311	Regulation of Cortical Interneurons by Neurotrophins: From Development to Cognitive Disorders. Neuroscientist, 2006, 12, 43-56.	2.6	114
312	Rat Modeling for GABA Defects in Schizophrenia. Advances in Pharmacology, 2006, 54, 73-93.	1.2	3

#	Article	IF	Citations
313	Region-Specific Reduction in Entorhinal Gamma Oscillations and Parvalbumin-Immunoreactive Neurons in Animal Models of Psychiatric Illness. Journal of Neuroscience, 2006, 26, 2767-2776.	1.7	173
314	Reversal of Brain Injury-Induced Prefrontal Glutamic Acid Decarboxylase Expression and Working Memory Deficits by D1 Receptor Antagonism. Journal of Neuroscience, 2006, 26, 4236-4246.	1.7	68
315	Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. Progress in Brain Research, 2006, 158, 141-152.	0.9	17
316	GABAergic Neurons Immunoreactive for Calcium Binding Proteins are Reduced in the Prefrontal Cortex in Major Depression. Neuropsychopharmacology, 2007, 32, 471-482.	2.8	354
317	NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons. Journal of Neuroscience, 2007, 27, 11496-11500.	1.7	1,063
318	Effects of Î³-Aminobutyric Acidâ€“Modulating Drugs on Working Memory and Brain Function in Patients With Schizophrenia. Archives of General Psychiatry, 2007, 64, 156.	13.8	116
319	Reviewing the Role of DNA (Cytosine-5) Methyltransferase Overexpression in the Cortical GABAergic Dysfunction Associated with Psychosis Vulnerability. Epigenetics, 2007, 2, 29-36.	1.3	86
320	Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4676-4681.	3.3	170
321	S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. NeuroReport, 2007, 18, 57-60.	0.6	89
322	Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 225-233.	2.5	79
323	The cellular and behavioral consequences of interleukin-1 alpha penetration through the bloodâ€“brain barrier of neonatal rats: A critical period for efficacy. Neuroscience, 2007, 150, 234-250.	1.1	23
324	Deciphering the Disease Process of Schizophrenia: The Contribution of Cortical Gaba Neurons. International Review of Neurobiology, 2007, 78, 109-131.	0.9	95
325	Molecular Mechanisms of Schizophrenia. Cellular Physiology and Biochemistry, 2007, 20, 687-702.	1.1	243
326	Searching for Unique Endophenotypes for Schizophrenia and Bipolar Disorder Within Neural Circuits and Their Molecular Regulatory Mechanisms. Schizophrenia Bulletin, 2007, 33, 932-936.	2.3	47
327	Caspase-3 Activation in Rat Frontal Cortex Following Treatment with Typical and Atypical Antipsychotics. Neuropsychopharmacology, 2007, 32, 95-102.	2.8	35
328	Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase. Science, 2007, 318, 1645-1647.	6.0	526
329	Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophrenia Research, 2007, 91, 51-61.	1.1	137
330	Systematic study of association of four GABAergic genes: Glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABAB receptor 1 gene and GABAA receptor subunit Î²2 gene, with schizophrenia using a universal DNA microarray. Schizophrenia Research, 2007, 93, 374-384.	1.1	42

#	Article	IF	Citations
331	Parvalbumin Neurons in the Entorhinal Cortex of Subjects Diagnosed With Bipolar Disorder or Schizophrenia. Biological Psychiatry, 2007, 61, 640-652.	0.7	72
332	Prefrontal Dysfunction in Schizophrenia Involves Mixed-Lineage Leukemia 1-Regulated Histone Methylation at GABAergic Gene Promoters. Journal of Neuroscience, 2007, 27, 11254-11262.	1.7	314
333	Late-Life Schizophrenia. , 0, , 59-77.		1
334	Association between the 5q31.1 gene neurogenin1 and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 207-214.	1.1	14
335	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Molecular Psychiatry, 2007, 12, 854-869.	4.1	248
336	The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Research Reviews, 2007, 56, 427-442.	9.1	96
337	Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders. Neurotoxicity Research, 2007, 12, 43-60.	1.3	23
338	Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex. Psychopharmacology, 2007, 192, 283-290.	1.5	56
339	Activation of GABAB receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. Psychopharmacology, 2007, 194, 361-369.	1.5	43
340	Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotoxicity Research, 2008, 14, 97-104.	1.3	89
341	Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotoxicity Research, 2008, 14, 237-248.	1.3	80
342	Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia. Journal of Neural Transmission, 2008, 115, 513-519.	1.4	27
343	Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry, 2008, 13, 147-161.	4.1	447
344	Changes in density of calciumâ€binding â€protein â€immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology, 2008, 28, 143-150.	0.7	104
345	Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation. BMC Neuroscience, 2008, 9, 41.	0.8	22
346	Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Research, 2008, 1218, 267-277.	1.1	116
347	Automated gray level index measurements reveal only minor cytoarchitectonic changes of Brodmann area 9 in schizophrenia. Psychiatry Research - Neuroimaging, 2008, 163, 183-192.	0.9	5
350	Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence. Australian and New Zealand Journal of Psychiatry, 2008, 42, 357-368.	1.3	80

#	Article	IF	Citations
351	Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia. Journal of Neuroscience, 2008, 28, 13957-13966.	1.7	220
352	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008, 31, 234-242.	4.2	896
353	Amphetamine sensitization in rats as an animal model of schizophrenia. Behavioural Brain Research, 2008, 191, 190-201.	1.2	55
354	Antiepileptic Drugs in Non-Epilepsy Disorders. CNS Drugs, 2008, 22, 27-47.	2.7	293
355	GABA Neurons and the Mechanisms of Network Oscillations: Implications for Understanding Cortical Dysfunction in Schizophrenia. Schizophrenia Bulletin, 2008, 34, 944-961.	2.3	500
356	Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13614-13619.	3.3	247
357	A Neonatal Ventral Hippocampal Lesion Causes Functional Deficits in Adult Prefrontal Cortical Interneurons. Journal of Neuroscience, 2008, 28, 12691-12699.	1.7	137
358	Alterations in Somatostatin mRNA Expression in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia or Schizoaffective Disorder. Cerebral Cortex, 2008, 18, 1575-1587.	1.6	178
359	A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Human Molecular Genetics, 2008, 17, 3030-3042.	1.4	239
360	Neuroplasticity of Neocortical Circuits in Schizophrenia. Neuropsychopharmacology, 2008, 33, 141-165.	2.8	329
361	Increased cortical inhibition in persons with schizophrenia treated with clozapine. Journal of Psychopharmacology, 2008, 22, 203-209.	2.0	79
362	Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia. Archives of General Psychiatry, 2008, 65, 772.	13.8	208
363	Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia. American Journal of Psychiatry, 2008, 165, 1585-1593.	4.0	264
364	Prolonged Exposure to NMDAR Antagonist Suppresses Inhibitory Synaptic Transmission in Prefrontal Cortex. Journal of Neurophysiology, 2008, 100, 959-965.	0.9	101
365	Neurobiology of the early course of schizophrenia. Expert Review of Neurotherapeutics, 2008, 8, 1093-1100.	1.4	14
366	Conserved Regional Patterns of GABA-Related Transcript Expression in the Neocortex of Subjects With Schizophrenia. American Journal of Psychiatry, 2008, 165, 479-489.	4.0	396
367	Altered Expression of Genes Involved in GABAergic Transmission and Neuromodulation of Granule Cell Activity in the Cerebellum of Schizophrenia Patients. American Journal of Psychiatry, 2008, 165, 1594-1603.	4.0	87
368	Modeling GABA Alterations in Schizophrenia: A Link Between Impaired Inhibition and Altered Gamma and Beta Range Auditory Entrainment. Journal of Neurophysiology, 2008, 99, 2656-2671.	0.9	180

#	Article	IF	Citations
369	Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Frontiers in Neural Circuits, 2009, 3, 20.	1.4	99
370	The Role of Prefrontal Abnormalities in Schizophrenia. , 2009, , 383-401.		1
371	Dopamine D₄Receptors Regulate AMPA Receptor Trafficking and Glutamatergic Transmission in GABAergic Interneurons of Prefrontal Cortex. Journal of Neuroscience, 2009, 29, 550-562.	1.7	69
372	Target Identification for CNS Diseases by Transcriptional Profiling. Neuropsychopharmacology, 2009, 34, 18-54.	2.8	138
373	Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics, 2009, 1, 201-211.	1.0	22
374	Steady State Responses: Electrophysiological Assessment of Sensory Function in Schizophrenia. Schizophrenia Bulletin, 2009, 35, 1065-1077.	2.3	199
375	Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide. Neuropsychopharmacology, 2009, 34, 1673-1684.	2.8	28
376	A Loss of Parvalbumin-Containing Interneurons Is Associated with Diminished Oscillatory Activity in an Animal Model of Schizophrenia. Journal of Neuroscience, 2009, 29, 2344-2354.	1.7	419
377	Brain abnormalities in schizophrenia. Medical Psychiatry, 2009, , 87-104.	0.2	1
378	Diminished Orientation-Specific Surround Suppression of Visual Processing in Schizophrenia. Schizophrenia Bulletin, 2009, 35, 1078-1084.	2.3	93
379	Decreased glutamic acid decarboxylase67 mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. Journal of Psychiatric Research, 2009, 43, 970-977.	1.5	166
380	Uncoupling of neurodegeneration and gliosis in a murine model of juvenile cortical lesion. Glia, 2009, 57, 693-702.	2.5	28
381	GABAA Receptor Downregulation in Brains of Subjects with Autism. Journal of Autism and Developmental Disorders, 2009, 39, 223-230.	1.7	385
382	Modeling â€œpsychosisâ€•in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology, 2009, 206, 575-585.	1.5	35
383	Zinc: The brain's dark horse. Synapse, 2009, 63, 1029-1049.	0.6	229
384	Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Medical Genetics, 2009, 10, 147.	2.1	18
385	Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry, 2009, 9, 71.	1.1	114
386	Clozapine, GABAB, and the Treatment of Resistant Schizophrenia. Clinical Pharmacology and Therapeutics, 2009, 86, 442-446.	2.3	50

#	Article	IF	Citations
387	NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: Application of laser microdissection technique. Journal of Neuroscience Methods, 2009, 176, 172-181.	1.3	59
388	Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. Expert Opinion on Drug Discovery, 2009, 4, 257-278.	2.5	6
390	Decreased learning ability and low hippocampus glutamate in offspring rats exposed to fluoride and lead. Environmental Toxicology and Pharmacology, 2009, 28, 254-258.	2.0	38
391	Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behavioural Brain Research, 2009, 204, 322-334.	1.2	141
392	Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia. Behavioural Brain Research, 2009, 204, 306-312.	1.2	204
393	Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends in Pharmacological Sciences, 2009, 30, 55-60.	4.0	123
394	GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology, 2009, 57, 481-495.	2.0	101
395	Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine. Neurochemistry International, 2009, 55, 775-782.	1.9	34
396	Molecular Determinants of Dysregulated GABAergic Gene Expression in the Prefrontal Cortex of Subjects with Schizophrenia. Biological Psychiatry, 2009, 65, 1006-1014.	0.7	246
397	Protracted Developmental Trajectories of GABAA Receptor Î±1 and Î±2 Subunit Expression in Primate Prefrontal Cortex. Biological Psychiatry, 2009, 65, 1015-1023.	0.7	134
398	Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophrenia Research, 2009, 111, 138-152.	1.1	49
399	An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophrenia Research, 2009, 111, 115-122.	1.1	117
400	NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder. Schizophrenia Research, 2009, 115, 261-269.	1.1	30
401	Repeated risperidone treatment increases the expression of NCAM and PSA-NCAM protein in the rat medial prefrontal cortex. European Neuropsychopharmacology, 2009, 19, 125-137.	0.3	18
402	Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. European Neuropsychopharmacology, 2009, 19, 256-265.	0.3	45
403	GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Review of Neurotherapeutics, 2009, 9, 87-98.	1.4	60
404	Mechanisms of Synapse Formation: Activity-Dependent Selection of Neurotransmitters and Receptors. , 2009, , 1-12.		0
405	The Neurodevelopmental Hypothesis of Schizophrenia, Revisited. Schizophrenia Bulletin, 2009, 35, 528-548.	2.3	679

#	Article	IF	Citations
406	Relationship of GAD₆₇regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus: Bipolar disorder versus schizophrenia. Cell Cycle, 2010, 9, 625-627.	1.3	14
407	Prefrontal Cortical Circuits in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 485-508.	0.8	90
408	Alterations of Cortical GABA Neurons and Network Oscillations in Schizophrenia. Current Psychiatry Reports, 2010, 12, 335-344.	2.1	235
409	Prefrontal GABAA receptor Î±-subunit expression in normal postnatal human development and schizophrenia. Journal of Psychiatric Research, 2010, 44, 673-681.	1.5	153
410	Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. , 2010, 128, 419-432.		463
411	Individual Differences in Subconscious Motor Control Predicted by GABA Concentration in SMA. Current Biology, 2010, 20, 1779-1785.	1.8	131
412	Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discovery Today, 2010, 15, 137-141.	3.2	10
413	Histone modifications, DNA methylation, and Schizophrenia. Neuroscience and Biobehavioral Reviews, 2010, 34, 882-888.	2.9	103
414	Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology, 2010, 159, 285-303.	2.7	55
415	Temporal dysregulation of cortical gene expression in the isolation reared Wistar rat. Journal of Neurochemistry, 2010, 113, 601-614.	2.1	18
416	Abnormal neural oscillations and synchrony in schizophrenia. Nature Reviews Neuroscience, 2010, 11, 100-113.	4.9	1,706
417	Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature, 2010, 468, 263-269.	13.7	1,042
418	Mapping synaptic pathology within cerebral cortical circuits in subjects with schizophrenia. Frontiers in Human Neuroscience, 2010, 4, 44.	1.0	27
419	Expression of the Rap1 Guanine Nucleotide Exchange Factor, MR-GEF, Is Altered in Individuals with Bipolar Disorder. PLoS ONE, 2010, 5, e10392.	1.1	9
420	Amygdalocortical Circuitry in Schizophrenia: From Circuits to Molecules. Neuropsychopharmacology, 2010, 35, 239-257.	2.8	155
421	Sex differences in brain epigenetics. Epigenomics, 2010, 2, 807-821.	1.0	69
422	Gamma Oscillation Deficits and the Onset and Early Progression of Schizophrenia. Harvard Review of Psychiatry, 2010, 18, 173-189.	0.9	86
423	Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia. Neuropsychopharmacology, 2010, 35, 258-277.	2.8	198

#	Article	IF	Citations
424	Review of Pathological Hallmarks of Schizophrenia: Comparison of Genetic Models With Patients and Nongenetic Models. Schizophrenia Bulletin, 2010, 36, 301-313.	2.3	125
425	Altered Cortical CDC42 Signaling Pathways in Schizophrenia: Implications for Dendritic Spine Deficits. Biological Psychiatry, 2010, 68, 25-32.	0.7	99
426	Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophrenia Research, 2010, 118, 292-299.	1.1	40
427	Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophrenia Research, 2010, 121, 146-152.	1.1	113
428	Maternal Care and DNA Methylation of a Glutamic Acid Decarboxylase 1 Promoter in Rat Hippocampus. Journal of Neuroscience, 2010, 30, 13130-13137.	1.7	250
429	Aberrant regulation of alternative pre-mRNA splicing in schizophrenia. Neurochemistry International, 2010, 57, 691-704.	1.9	35
430	The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits. Brain Research Bulletin, 2010, 83, 122-131.	1.4	146
431	Knockdown of DISC1 by In Utero Gene Transfer Disturbs Postnatal Dopaminergic Maturation in the Frontal Cortex and Leads to Adult Behavioral Deficits. Neuron, 2010, 65, 480-489.	3.8	275
432	Developmental emergence of reelin deficits in the prefrontal cortex of Wistar rats reared in social isolation. Neuroscience, 2010, 166, 377-385.	1.1	22
433	GABA Concentration Is Reduced in Visual Cortex in Schizophrenia and Correlates with Orientation-Specific Surround Suppression. Journal of Neuroscience, 2010, 30, 3777-3781.	1.7	353
434	Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, 2010, , .	0.8	8
435	Epigenetic Studies of Psychosis: Current Findings, Methodological Approaches, and Implications for Postmortem Research. Biological Psychiatry, 2011, 69, 146-156.	0.7	104
436	Increased Interstitial White Matter Neuron Density in the Dorsolateral Prefrontal Cortex of People with Schizophrenia. Biological Psychiatry, 2011, 69, 63-70.	0.7	99
437	Reducing Prefrontal Gamma-Aminobutyric Acid Activity Induces Cognitive, Behavioral, and Dopaminergic Abnormalities That Resemble Schizophrenia. Biological Psychiatry, 2011, 69, 432-441.	0.7	147
438	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. Biological Psychiatry, 2011, 69, 442-449.	0.7	155
440	Schizophrenia: Treatment Targets Beyond Monoamine Systems. Annual Review of Pharmacology and Toxicology, 2011, 51, 189-209.	4.2	56
441	Dysbindin Câ€“Aâ€“T haplotype is associated with thicker medial orbitofrontal cortex in healthy population. NeuroImage, 2011, 55, 508-513.	2.1	12
443	Modeling Schizophrenia in Neuregulin 1 and ErbB4 Mutant Mice. Neuromethods, 2011, , 261-277.	0.2	0

#	Article	IF	Citations
444	Is DNA methylation responsible for immune system dysfunction in schizophrenia?. Medical Hypotheses, 2011, 77, 573-579.	0.8	3
445	Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neuroscience Letters, 2011, 488, 267-271.	1.0	29
446	White matter neuron alterations in schizophrenia and related disorders. International Journal of Developmental Neuroscience, 2011, 29, 325-334.	0.7	66
447	Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry. International Journal of Developmental Neuroscience, 2011, 29, 295-304.	0.7	44
448	Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Progress in Neurobiology, 2011, 95, 275-300.	2.8	113
449	Analysis of the GAD1 promoter: Trans-acting factors and DNA methylation converge on the 5â€² untranslated region. Neuropharmacology, 2011, 60, 1075-1087.	2.0	36
450	Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology, 2011, 60, 1007-1016.	2.0	192
451	The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology, 2011, 60, 1221-1226.	2.0	67
452	Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders. Neuropharmacology, 2011, 60, 1232-1242.	2.0	34
453	Broader Visual Orientation Tuning in Patients with Schizophrenia. Frontiers in Human Neuroscience, 2011, 5, 127.	1.0	43
454	Brain-derived neurotrophic factor: findings in schizophrenia. Current Opinion in Psychiatry, 2011, 24, 122-127.	3.1	116
457	Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice. European Journal of Neuroscience, 2011, 33, 689-698.	1.2	38
458	The GABA_B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. British Journal of Pharmacology, 2011, 163, 1034-1047.	2.7	28
459	Expression of VGluT1 and VGAT mRNAs in human dorsolateral prefrontal cortex during development and in schizophrenia. Brain Research, 2011, 1388, 22-31.	1.1	22
460	Gamma oscillations in schizophrenia: Mechanisms and clinical significance. Brain Research, 2011, 1413, 98-114.	1.1	98
461	Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathologica, 2011, 122, 615-626.	3.9	110
462	Prenatal stress: Role in psychotic and depressive diseases. Psychopharmacology, 2011, 214, 89-106.	1.5	223
463	Goodbye to Edward G. (Ted) Jones, MD, DPhil, 1939â€2011. Journal of Comparative Neurology, 2011, 519, 3125-3127.	0.9	0

#	Article	IF	Citations
464	Interneurons in the developing human neocortex. Developmental Neurobiology, 2011, 71, 18-33.	1.5	118
465	The chandelier neuron in schizophrenia. Developmental Neurobiology, 2011, 71, 118-127.	1.5	70
466	How feedback inhibition shapes spike-timing-dependent plasticity and its implications for recent Schizophrenia models. Neural Networks, 2011, 24, 560-567.	3.3	5
467	Increased density of GAD65/67 immunoreactive neurons in the posterior subiculum and parahippocampal gyrus in treated patients with chronic schizophrenia. World Journal of Biological Psychiatry, 2011, 12, 57-65.	1.3	24
468	Lamina-Specific Alterations in Cortical GABAA Receptor Subunit Expression in Schizophrenia. Cerebral Cortex, 2011, 21, 999-1011.	1.6	115
469	Cortical Deficits of Glutamic Acid Decarboxylase 67 Expression in Schizophrenia: Clinical, Protein, and Cell Type-Specific Features. American Journal of Psychiatry, 2011, 168, 921-929.	4.0	237
470	Postnatal Developmental Trajectories of Neural Circuits in the Primate Prefrontal Cortex: Identifying Sensitive Periods for Vulnerability to Schizophrenia. Schizophrenia Bulletin, 2011, 37, 493-503.	2.3	109
471	Selective Î±4Î²2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons. Neuropsychopharmacology, 2011, 36, 1366-1374.	2.8	36
472	Reduced Neuronal Inhibition and Coordination of Adolescent Prefrontal Cortex during Motivated Behavior. Journal of Neuroscience, 2011, 31, 1471-1478.	1.7	56
473	Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Translational Psychiatry, 2011, 1, e64-e64.	2.4	113
474	Genetics and Function of Neocortical GABAergic Interneurons in Neurodevelopmental Disorders. Neural Plasticity, 2011, 2011, 1-25.	1.0	181
475	Contribution of nonprimate animal models in understanding the etiology of schizophrenia. Journal of Psychiatry and Neuroscience, 2011, 36, E5-E29.	1.4	14
476	Abnormal Gamma and Beta MEG Activity During Finger Movements in Early-Onset Psychosis. Developmental Neuropsychology, 2011, 36, 596-613.	1.0	57
477	Early Origins of Adult Disease: Approaches for Investigating the Programmable Epigenome in Humans, Nonhuman Primates, and Rodents. ILAR Journal, 2012, 53, 306-321.	1.8	57
478	Growth Arrest and DNA-Damage-Inducible, Beta (GADD45b)-Mediated DNA Demethylation in Major Psychosis. Neuropsychopharmacology, 2012, 37, 531-542.	2.8	102
479	Selective overexpression of Comt in prefrontal cortex rescues schizophrenia-like phenotypes in a mouse model of 22q11 deletion syndrome. Translational Psychiatry, 2012, 2, e146-e146.	2.4	36
480	Transcript-Specific Associations of SLC12A5 (KCC2) in Human Prefrontal Cortex with Development, Schizophrenia, and Affective Disorders. Journal of Neuroscience, 2012, 32, 5216-5222.	1.7	84
481	The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia. Reviews in the Neurosciences, 2012, 23, 97-109.	1.4	62

#	Article	IF	Citations
482	Cortical Opioid Markers in Schizophrenia and across Postnatal Development. Cerebral Cortex, 2012, 22, 1215-1223.	1.6	43
483	Inhibitory Interneurons, Oxidative Stress, and Schizophrenia. Schizophrenia Bulletin, 2012, 38, 373-376.	2.3	60
484	Elevated Prefrontal Cortex Î³-Aminobutyric Acid and Glutamate-Glutamine Levels in Schizophrenia Measured In Vivo With Proton Magnetic Resonance Spectroscopy. Archives of General Psychiatry, 2012, 69, 449.	13.8	294
485	Altered Cortical GABA Neurotransmission in Schizophrenia: Insights into Novel Therapeutic Strategies. Current Pharmaceutical Biotechnology, 2012, 13, 1557-1562.	0.9	65
486	Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients. Neuroscience Letters, 2012, 530, 97-102.	1.0	89
487	Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology, 2012, 62, 1422-1431.	2.0	73
488	A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology, 2012, 62, 1767-1776.	2.0	82
489	Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences, 2012, 35, 57-67.	4.2	892
490	Deficits in Transcriptional Regulators of Cortical Parvalbumin Neurons in Schizophrenia. American Journal of Psychiatry, 2012, 169, 1082-1091.	4.0	135
491	Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications. Handbook of Experimental Pharmacology, 2012, , 267-295.	0.9	149
492	Neurons on the Move: Migration and Lamination of Cortical Interneurons. NeuroSignals, 2012, 20, 168-189.	0.5	67
493	Modeling Interneuron Dysfunction in Schizophrenia. Developmental Neuroscience, 2012, 34, 152-158.	1.0	12
494	Interneuron dysfunction in psychiatric disorders. Nature Reviews Neuroscience, 2012, 13, 107-120.	4.9	978
495	Cortical Glutamic Acid Decarboxylase 67 Deficiency Results in Lower Cannabinoid 1 Receptor Messenger RNA Expression: Implications for Schizophrenia. Biological Psychiatry, 2012, 71, 114-119.	0.7	19
496	Higher Gamma-Aminobutyric Acid Neuron Density in the White Matter of Orbital Frontal Cortex in Schizophrenia. Biological Psychiatry, 2012, 72, 725-733.	0.7	70
497	On a Quest for the Elusive Schizophrenia Biomarker. Biological Psychiatry, 2012, 72, 714-715.	0.7	5
498	Optogenetic dissection of cortical information processing-shining light on schizophrenia. Brain Research, 2012, 1476, 31-37.	1.1	12
499	Multifaceted genomic risk for brain function in schizophrenia. NeuroImage, 2012, 61, 866-875.	2.1	42

#	Article	IF	Citations
500	Activity-dependent neurotransmitter respecification. Nature Reviews Neuroscience, 2012, 13, 94-106.	4.9	136
501	Human prefrontal cortex. Progress in Brain Research, 2012, 195, 191-218.	0.9	274
502	Development of the GABAergic System from Birth to Adolescence. Neuroscientist, 2012, 18, 613-630.	2.6	145
503	The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders. Frontiers in Psychiatry, 2012, 3, 39.	1.3	98
504	The neurobiology of chromatin-associated mechanisms in the context of psychosis and mood spectrum disorders. , 0, , 420-433.		0
505	Epigenetic effects of childhood abuse on the human brain. , 0, , 461-482.		1
506	Synaptic Dysfunction in Schizophrenia. Advances in Experimental Medicine and Biology, 2012, 970, 493-516.	0.8	67
507	A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Annals of the New York Academy of Sciences, 2012, 1248, 89-106.	1.8	86
508	Transcranial magnetic stimulation on the modulation of gamma oscillations in schizophrenia. Annals of the New York Academy of Sciences, 2012, 1265, 25-35.	1.8	41
509	The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiology of Disease, 2012, 45, 23-36.	2.1	62
510	Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiology of Disease, 2012, 46, 255-262.	2.1	41
511	Post-weaning social isolation and subchronic NMDA glutamate receptor blockade: Effects on locomotor activity and GABA signaling in the rat suggest independent mechanisms. Pharmacology Biochemistry and Behavior, 2012, 101, 231-238.	1.3	31
512	Cortical circuit dysfunction and cognitive deficits in schizophrenia â€“ implications for preemptive interventions. European Journal of Neuroscience, 2012, 35, 1871-1878.	1.2	130
513	Abnormal interneuron development in disrupted-in-schizophrenia-1 L100P mutant mice. Molecular Brain, 2013, 6, 20.	1.3	44
514	Development and specification of GABAergic cortical interneurons. Cell and Bioscience, 2013, 3, 19.	2.1	136
515	Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1. Psychopharmacology, 2013, 227, 673-683.	1.5	19
516	Combination of prenatal immune challenge and restraint stress affects prepulse inhibition and dopaminergic/GABAergic markers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 156-164.	2.5	51
517	The Mind and its Nucleosomes â€“ Chromatin (dys)Regulation in Major Psychiatric Disease. , 2013, , 197-222.		0

#	Article	IF	Citations
518	Impaired GABAergic Neurotransmission in Schizophrenia Underlies Impairments in Cortical Gamma Band Oscillations. Current Psychiatry Reports, 2013, 15, 346.	2.1	42
519	Measuring GABAergic Inhibitory Activity with TMS-EEG and Its Potential Clinical Application for Chronic Pain. Journal of NeuroImmune Pharmacology, 2013, 8, 535-546.	2.1	43
520	Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience, 2013, 248, 154-164.	1.1	49
521	DHA prevents altered 5-HT1A, 5-HT2A, CB1 and GABAA receptor binding densities in the brain of male rats fed a high-saturated-fat diet. Journal of Nutritional Biochemistry, 2013, 24, 1349-1358.	1.9	12
522	Modeling Schizophrenia in Animals. , 2013, , 727-755.		6
523	Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.	3.8	254
524	Classification and function of GABAergic interneurons of the mammalian cerebral cortex. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2013, 7, 245-259.	0.3	2
525	Environmental Epigenomics in Health and Disease. Epigenetics and Human Health, 2013, , .	0.2	3
526	Losing your inhibition: Linking cortical GABAergic interneurons to schizophrenia. Neurobiology of Disease, 2013, 53, 36-48.	2.1	97
527	Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophrenia Research, 2013, 147, 53-57.	1.1	32
528	Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia. Neurobiology of Disease, 2013, 50, 179-186.	2.1	52
529	A â€œdouble hitâ€•murine model for schizophrenia shows alterations in the structure and neurochemistry of the medial prefrontal cortex and the hippocampus. Neurobiology of Disease, 2013, 59, 126-140.	2.1	41
530	Synapse-specific contributions in the cortical pathology of schizophrenia. Neurobiology of Disease, 2013, 53, 26-35.	2.1	27
531	GABAergic Interneurons Shape the Functional Maturation of the Cortex. Neuron, 2013, 77, 388-405.	3.8	367
532	Increased spontaneous gamma power and synchrony in schizophrenia patients having higher minor physical anomalies. Psychiatry Research, 2013, 207, 164-172.	1.7	22
533	The Dynamics of DNA Methylation in Schizophrenia and Related Psychiatric Disorders. Neuropsychopharmacology, 2013, 38, 138-166.	2.8	241
534	Histone methylation at H3K9: Evidence for a restrictive epigenome in schizophrenia. Schizophrenia Research, 2013, 149, 15-20.	1.1	92
535	Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus. Journal of Psychiatric Research, 2013, 47, 872-879.	1.5	9

#	Article	IF	Citations
537	Associations between prefrontal Î³-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women. International Journal of Neuropsychopharmacology, 2013, 16, 1707-1717.	1.0	12
538	A Proposal for Reframing Schizophrenia Research. Journal of Nervous and Mental Disease, 2013, 201, 744-752.	0.5	9
539	Opposing Alterations in Excitation and Inhibition of Layer 5 Medial Prefrontal Cortex Pyramidal Neurons Following Neonatal Ventral Hippocampal Lesion. Cerebral Cortex, 2013, 23, 1198-1207.	1.6	20
540	Phencyclidine-Induced Decrease of Synaptic Connectivity via Inhibition of BDNF Secretion in Cultured Cortical Neurons. Cerebral Cortex, 2013, 23, 847-858.	1.6	29
541	Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. Journal of Neurochemistry, 2013, 126, 165-182.	2.1	106
542	Enhanced hippocampal neuronal excitability and LTP persistence associated with reduced behavioral flexibility in the maternal immune activation model of schizophrenia. Hippocampus, 2013, 23, 1395-1409.	0.9	50
543	Conserved Chromosome 2q31 Conformations Are Associated with Transcriptional Regulation of GAD1 GABA Synthesis Enzyme and Altered in Prefrontal Cortex of Subjects with Schizophrenia. Journal of Neuroscience, 2013, 33, 11839-11851.	1.7	60
544	A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia. Translational Psychiatry, 2013, 3, e215-e215.	2.4	69
545	Synaptic inhibition and Î³-aminobutyric acid in the mammalian central nervous system. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2013, 89, 139-156.	1.6	60
546	Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia Are Linked to Î±4 and Î²2S mRNA Levels Respectively. PLoS ONE, 2013, 8, e52724.	1.1	18
547	High-frequency neural oscillations and visual processing deficits in schizophrenia. Frontiers in Psychology, 2013, 4, 621.	1.1	43
548	Windows to the soul: vision science as a tool for studying biological mechanisms of information processing deficits in schizophrenia. Frontiers in Psychology, 2013, 4, 681.	1.1	39
549	Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Frontiers in Cellular Neuroscience, 2013, 7, 95.	1.8	36
550	Pathophysiological power of improper tonic GABAA conductances in mature and immature models. Frontiers in Neural Circuits, 2013, 7, 170.	1.4	49
551	Trajectory of the main GABAergic interneuron populations from early development to old age in the rat primary auditory cortex. Frontiers in Neuroanatomy, 2014, 8, 40.	0.9	64
552	Modulatory effects of inhibition on persistent activity in a cortical microcircuit model. Frontiers in Neural Circuits, 2014, 8, 7.	1.4	29
553	Multisensory stimuli elicit altered oscillatory brain responses at gamma frequencies in patients with schizophrenia. Frontiers in Human Neuroscience, 2014, 8, 788.	1.0	12
554	Vagal Nerve Stimulation Reverses Aberrant Dopamine System Function in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia. Journal of Neuroscience, 2014, 34, 9261-9267.	1.7	49

#	Article	IF	Citations
555	Selective loss of parvalbumin-positive GABAergic interneurons in the cerebral cortex of maternally stressed Gad1-heterozygous mouse offspring. Translational Psychiatry, 2014, 4, e371-e371.	2.4	65
556	The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis. Frontiers in Pharmacology, 2014, 5, 277.	1.6	4
557	Modeling the Molecular Epigenetic Profile of Psychosis in Prenatally Stressed Mice. Progress in Molecular Biology and Translational Science, 2014, 128, 89-101.	0.9	20
559	Lower Expression of Glutamic Acid Decarboxylase 67 in the Prefrontal Cortex in Schizophrenia: Contribution of Altered Regulation by Zif268. American Journal of Psychiatry, 2014, 171, 969-978.	4.0	69
560	Oxidative stress and schizophrenia. Current Opinion in Psychiatry, 2014, 27, 185-190.	3.1	157
561	Immune System Disturbances in Schizophrenia. Biological Psychiatry, 2014, 75, 316-323.	0.7	163
562	Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia. Molecular Psychiatry, 2014, 19, 478-485.	4.1	105
563	Kv3.1-containing K+ channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Molecular Psychiatry, 2014, 19, 573-579.	4.1	65
564	Cortical Inhibitory Neuron Disturbances in Schizophrenia: Role of the Ontogenetic Transcription Factor Lhx6. Schizophrenia Bulletin, 2014, 40, 1053-1061.	2.3	22
565	Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia. Journal of Neurogenetics, 2014, 28, 41-52.	0.6	45
566	Prefrontal Cortical GABA Transmission Modulates Discrimination and Latent Inhibition of Conditioned Fear: Relevance for Schizophrenia. Neuropsychopharmacology, 2014, 39, 2473-2484.	2.8	34
567	Cortical Inhibition, Excitation, and Connectivity in Schizophrenia: A Review of Insights From Transcranial Magnetic Stimulation. Schizophrenia Bulletin, 2014, 40, 685-696.	2.3	63
568	Transcriptional dysregulation of Î³-aminobutyric acid transporter in parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. Psychiatry Research, 2014, 220, 1155-1159.	1.7	11
569	Parvalbumin and GAD65 Interneuron Inhibition in the Ventral Hippocampus Induces Distinct Behavioral Deficits Relevant to Schizophrenia. Journal of Neuroscience, 2014, 34, 14948-14960.	1.7	78
570	Association of intracortical inhibition with social cognition deficits in schizophrenia: Findings from a transcranial magnetic stimulation study. Schizophrenia Research, 2014, 158, 146-150.	1.1	16
571	The Epigenetics of Suicide. , 2014, , 303-324.		0
572	Alterations in the hippocampal and striatal catecholaminergic fiber densities of heterozygous reeler mice. Neuroscience, 2014, 275, 404-419.	1.1	9
573	Prenatal stress and inhibitory neuron systems: implications for neuropsychiatric disorders. Molecular Psychiatry, 2014, 19, 641-651.	4.1	85

#	Article	IF	Citations
574	Diverse Epigenetic Mechanisms of Human Disease. Annual Review of Genetics, 2014, 48, 237-268.	3.2	107
575	The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat. Psychopharmacology, 2014, 231, 2001-2008.	1.5	29
576	Neural oscillations during nonâ€rapid eye movement sleep as biomarkers of circuit dysfunction in schizophrenia. European Journal of Neuroscience, 2014, 39, 1091-1106.	1.2	36
577	Epigenetic Dysregulation in the Schizophrenic Brain. Current Behavioral Neuroscience Reports, 2014, 1, 86-93.	0.6	3
578	High White Matter Neuron Density with Elevated Cortical Cytokine Expression in Schizophrenia. Biological Psychiatry, 2014, 75, e5-e7.	0.7	36
579	Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers. Schizophrenia Research, 2014, 155, 26-30.	1.1	85
580	Elevated Viral Restriction Factor Levels in Cortical Blood Vessels in Schizophrenia. Biological Psychiatry, 2014, 76, 160-167.	0.7	35
581	New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases. World Journal of Biological Chemistry, 2014, 5, 409.	1.7	132
582	Spectral editing in proton magnetic resonance spectroscopy. Determination of GABA level in the brains of humans with ultra-high risk for schizophrenia. Russian Chemical Bulletin, 2015, 64, 2238-2243.	0.4	2
583	Relationship between somatostatin and death receptor expression in the orbital frontal cortex in schizophrenia: a postmortem brain mRNA study. NPJ Schizophrenia, 2015, 1, 14004.	2.0	25
584	Ageâ€dependent loss of parvalbuminâ€expressing hippocampal interneurons in mice deficient in <scp>CHL</scp>1, a mental retardation and schizophrenia susceptibility gene. Journal of Neurochemistry, 2015, 135, 830-844.	2.1	48
585	Epigenetic Mechanisms in the Pathophysiology of Psychotic Disorders. Harvard Review of Psychiatry, 2015, 23, 212-222.	0.9	7
586	Neuronal migration abnormalities and its possible implications for schizophrenia. Frontiers in Neuroscience, 2015, 9, 74.	1.4	68
587	Associating schizophrenia, long non-coding RNAs and neurostructural dynamics. Frontiers in Molecular Neuroscience, 2015, 8, 57.	1.4	30
588	Phencyclidine Disrupts the Auditory Steady State Response in Rats. PLoS ONE, 2015, 10, e0134979.	1.1	30
589	Prefrontal Cortex and Social Cognition in Mouse and Man. Frontiers in Psychology, 2015, 6, 1805.	1.1	354
590	Evidence of a sex-dependent restrictive epigenome in schizophrenia. Journal of Psychiatric Research, 2015, 65, 87-94.	1.5	32
591	Chemical Neurotransmission. , 2015, , 63-131.		1

#	Article	IF	Citations
592	Circuit- and Diagnosis-Specific DNA Methylation Changes at Î³-Aminobutyric Acidâ€“Related Genes in Postmortem Human Hippocampus in Schizophrenia and Bipolar Disorder. JAMA Psychiatry, 2015, 72, 541.	6.0	97
593	Prefrontal Cortical GABA Modulation of Spatial Reference and Working Memory. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	41
594	Neurotransmitter Switching? No Surprise. Neuron, 2015, 86, 1131-1144.	3.8	78
595	Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophrenia Research, 2015, 167, 57-63.	1.1	29
596	Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. Molecular Psychiatry, 2015, 20, 1499-1507.	4.1	84
597	Clozapine and GABA transmission in schizophrenia disease models. , 2015, 150, 47-80.		38
598	The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophrenia Research, 2015, 167, 98-107.	1.1	184
599	Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences, 2015, 69, 243-258.	1.0	138
600	Prefrontal Cortical Gamma-Aminobutyric Acid Transmission and Cognitive Function: Drawing Links to Schizophrenia from Preclinical Research. Biological Psychiatry, 2015, 77, 929-939.	0.7	56
601	Human pluripotent stem cells as tools for high-throughput and high-content screening in drug discovery. International Journal of High Throughput Screening, 0, , 1.	0.5	1
602	The neuropathology of schizophrenia: A selective review of past studies and emerging themes in brain structure and cytoarchitecture. Neuroscience, 2015, 303, 82-102.	1.1	100
603	Building models for postmortem abnormalities in hippocampus of schizophrenics. Schizophrenia Research, 2015, 167, 73-83.	1.1	22
604	Translating the MAM model of psychosis to humans. Trends in Neurosciences, 2015, 38, 129-138.	4.2	139
605	Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia. Schizophrenia Research, 2015, 167, 28-34.	1.1	50
606	Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions. Development and Psychopathology, 2015, 27, 615-635.	1.4	59
608	Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia. Biological Psychiatry, 2015, 77, 1031-1040.	0.7	409
609	Converging models of schizophrenia â€“ Network alterations of prefrontal cortex underlying cognitive impairments. Progress in Neurobiology, 2015, 134, 178-201.	2.8	71
610	Adolescent testosterone influences BDNF and TrkB mRNA and neurotrophinâ€“interneuron marker relationships in mammalian frontal cortex. Schizophrenia Research, 2015, 168, 661-670.	1.1	16

#	Article	IF	Citations
611	Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. Translational Psychiatry, 2015, 5, e522-e522.	2.4	51
612	Effects of NMDA and GABA-A Receptor Antagonism on Auditory Steady-State Synchronization in Awake Behaving Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu118-pyu118.	1.0	51
613	Abnormal subcellular localization of GABAA receptor subunits in schizophrenia brain. Translational Psychiatry, 2015, 5, e612-e612.	2.4	33
614	Evidence for inhibitory deficits in the prefrontal cortex in schizophrenia. Brain, 2015, 138, 483-497.	3.7	63
615	DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophrenia Research, 2015, 167, 35-41.	1.1	79
616	Chemokine receptors and cortical interneuron dysfunction in schizophrenia. Schizophrenia Research, 2015, 167, 12-17.	1.1	28
617	GABA abnormalities in schizophrenia: A methodological review of in vivo studies. Schizophrenia Research, 2015, 167, 84-90.	1.1	99
618	Altered Cortical Expression of GABA-Related Genes in Schizophrenia: Illness Progression vs Developmental Disturbance. Schizophrenia Bulletin, 2015, 41, 180-191.	2.3	117
619	GAD67 Deficiency in Parvalbumin Interneurons Produces Deficits in Inhibitory Transmission and Network Disinhibition in Mouse Prefrontal Cortex. Cerebral Cortex, 2015, 25, 1290-1296.	1.6	93
620	Lower Glutamic Acid Decarboxylase 65-kDa Isoform Messenger RNA and Protein Levels in the Prefrontal Cortex in Schizoaffective Disorder but Not Schizophrenia. Biological Psychiatry, 2015, 77, 167-176.	0.7	43
621	Neurodevelopment, GABA System Dysfunction, and Schizophrenia. Neuropsychopharmacology, 2015, 40, 190-206.	2.8	172
623	Distinct Physiological Effects of Dopamine D4 Receptors on Prefrontal Cortical Pyramidal Neurons and Fast-Spiking Interneurons. Cerebral Cortex, 2016, 26, 180-191.	1.6	41
624	Neurometabolic Profiling of Ketamine. , 2016, , 573-580.		0
625	Psychosis Induced by Phencyclidine (Also Called PCP or Angel Dust). , 2016, , 703-713.		0
626	Multifactorial Modeling of Impairment of Evoked Gamma Range Oscillations in Schizophrenia. Frontiers in Computational Neuroscience, 2016, 10, 89.	1.2	16
627	REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular. Current Neuropharmacology, 2016, 14, 28-40.	1.4	11
628	The Convergence of Glutamate and GABA Dysregulation in Schizophrenia. , 2016, , .		0
629	Modeling Geneâ€“Environment Interaction in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 345-360.	0.7	2

#	Article	IF	Citations
630	Distinct cortical and striatal actions of a Î²-arrestinâ€“biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8178-E8186.	3.3	117
631	Using Induced Pluripotent Stem Cells to Investigate Complex Genetic Psychiatric Disorders. Current Behavioral Neuroscience Reports, 2016, 3, 275-284.	0.6	6
632	Prenatal phencyclidine treatment induces behavioral deficits through impairment of GABAergic interneurons in the prefrontal cortex. Psychopharmacology, 2016, 233, 2373-2381.	1.5	25
633	Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade. Cell Reports, 2016, 17, 570-582.	2.9	65
634	GABAergic mRNA expression is differentially expressed across the prelimbic and orbitofrontal cortices of rats sensitized to methamphetamine: Relevance to psychosis. Neuropharmacology, 2016, 111, 107-118.	2.0	17
635	Bacopa monnieri (Brahmi) improved novel object recognition task and increased cerebral vesicular glutamate transporter type 3 in subâ€chronic phencyclidine rat model of schizophrenia. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 1234-1242.	0.9	14
636	Acute phencyclidine administration induces c-Fos-immunoreactivity in interneurons in cortical and subcortical regions. Neuroscience, 2016, 334, 13-25.	1.1	13
637	Dorsolateral Prefrontal Cortex GABA Concentration in Humans Predicts Working Memory Load Processing Capacity. Journal of Neuroscience, 2016, 36, 11788-11794.	1.7	93
638	Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy. Advances in Neurobiology, 2016, 12, 1-25.	1.3	10
639	Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia. American Journal of Psychiatry, 2016, 173, 1131-1139.	4.0	124
640	1H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients. Doklady Biochemistry and Biophysics, 2016, 468, 168-172.	0.3	20
641	Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders. Psychological Medicine, 2016, 46, 2501-2512.	2.7	42
642	Novel Targets for Drug Treatment in Psychiatry. , 2016, , 601-654.		0
643	A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment. Psychopharmacology, 2016, 233, 2151-2163.	1.5	45
644	Sensory-Derived Glutamate Regulates Presynaptic Inhibitory Terminals in Mouse Spinal Cord. Neuron, 2016, 90, 1189-1202.	3.8	40
645	Alterations in Prefrontal Cortical Circuitry and Cognitive Dysfunction in Schizophrenia. Nebraska Symposium on Motivation, 2016, 63, 31-75.	0.9	10
646	Markedly Lower Glutamic Acid Decarboxylase 67 Protein Levels in a Subset of Boutons in Schizophrenia. Biological Psychiatry, 2016, 79, 1006-1015.	0.7	45
647	Immunocytochemical heterogeneity of somatostatinâ€expressing GABAergic interneurons in layers II and III of the mouse cingulate cortex: A combined immunofluorescence/designâ€based stereologic study. Journal of Comparative Neurology, 2016, 524, 2281-2299.	0.9	15

#	Article	IF	Citations
648	Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study. Molecular Psychiatry, 2016, 21, 198-204.	4.1	93
649	Perturbations in reward-related decision-making induced by reduced prefrontal cortical GABA transmission: Relevance for psychiatric disorders. Neuropharmacology, 2016, 101, 279-290.	2.0	32
650	Toward dissecting the etiology of schizophrenia: HDAC1 and DAXX regulate GAD67 expression in an in vitro hippocampal GABA neuron model. Translational Psychiatry, 2016, 6, e723-e723.	2.4	18
651	Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions. Brain, Behavior, and Immunity, 2016, 54, 260-277.	2.0	99
652	Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Molecular Psychiatry, 2016, 21, 956-968.	4.1	167
653	Cortical Gene Expression After a Conditional Knockout of 67 kDa Glutamic Acid Decarboxylase in Parvalbumin Neurons. Schizophrenia Bulletin, 2016, 42, 992-1002.	2.3	19
654	Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection. Journal of NeuroImmune Pharmacology, 2016, 11, 279-293.	2.1	29
655	Increased white matter neuron density in a rat model of maternal immune activation â€" Implications for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 118-126.	2.5	28
656	Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Molecular Psychiatry, 2016, 21, 10-28.	4.1	85
657	Animal models of geneâ€"environment interaction in schizophrenia: A dimensional perspective. Progress in Neurobiology, 2016, 136, 1-27.	2.8	67
658	Neuroligin-2 Expression in the Prefrontal Cortex is Involved in Attention Deficits Induced by Peripubertal Stress. Neuropsychopharmacology, 2016, 41, 751-761.	2.8	31
659	Imbalance of excitatory/inhibitory synaptic protein expression in iPSC-derived neurons from FOXG1+/â^' patients and in foxg1+/â^' mice. European Journal of Human Genetics, 2016, 24, 871-880.	1.4	54
660	The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological Psychiatry, 2016, 79, 595-603.	0.7	53
661	Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia. Biological Psychiatry, 2016, 79, 716-726.	0.7	103
662	Using human brain imaging studies as a guide toward animal models of schizophrenia. Neuroscience, 2016, 321, 77-98.	1.1	26
663	GABA-Synthesizing Enzymes in Calbindin and Calretinin Neurons in Monkey Prefrontal Cortex. Cerebral Cortex, 2016, 26, 2191-2204.	1.6	30
664	Morphological, structural, and functional alterations of the prefrontal cortex and the basolateral amygdala after early lesion of the rat mediodorsal thalamus. Brain Structure and Function, 2017, 222, 2527-2545.	1.2	17
665	Genetic Otx2 mis-localization delays critical period plasticity across brain regions. Molecular Psychiatry, 2017, 22, 680-688.	4.1	67

#	Article	IF	Citations
666	The space where aging acts: focus on the <scp>GABA</scp>ergic synapse. Aging Cell, 2017, 16, 634-643.	3.0	134
667	Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 2017, 124, 89-104.	2.0	140
668	Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis. Translational Psychiatry, 2017, 7, e1147-e1147.	2.4	122
669	Epidermal growth factor signals attenuate phenotypic and functional development of neocortical <scp>GABA</scp> neurons. Journal of Neurochemistry, 2017, 142, 886-900.	2.1	16
670	GABA_A and GABA_B receptor dysregulation in superior frontal cortex of subjects with schizophrenia and bipolar disorder. Synapse, 2017, 71, e21973.	0.6	26
671	Neurotransmitter Switching in the Developing and Adult Brain. Annual Review of Neuroscience, 2017, 40, 1-19.	5.0	94
672	Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiology of Disease, 2017, 99, 58-65.	2.1	39
673	Cortical interneuron development: a tale of time and space. Development (Cambridge), 2017, 144, 3867-3878.	1.2	166
674	Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function. Scientific Reports, 2017, 7, 11420.	1.6	91
675	Regulation of sustained attention, false alarm responding and implementation of conditional rules by prefrontal GABAA transmission: comparison with NMDA transmission. Psychopharmacology, 2017, 234, 2777-2792.	1.5	14
676	The Influence of Fluorine on the Disturbances of Homeostasis in the Central Nervous System. Biological Trace Element Research, 2017, 177, 224-234.	1.9	113
677	Alterations in a Unique Class of Cortical Chandelier Cell Axon Cartridges in Schizophrenia. Biological Psychiatry, 2017, 82, 40-48.	0.7	33
678	Epigenetic Regulation of Glutamic Acid Decarboxylase 67 in a Hippocampal Circuit. Cerebral Cortex, 2017, 27, 5284-5293.	1.6	5
679	New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. Biological Psychiatry, 2017, 81, 78-85.	0.7	99
680	Cell-based therapies for the treatment of schizophrenia. Brain Research, 2017, 1655, 262-269.	1.1	12
681	Prefrontal cortical GABAergic and NMDA glutamatergic regulation of delayed responding. Neuropharmacology, 2017, 113, 10-20.	2.0	23
682	Neurophysiology and Regulation of the Balance Between Excitation and Inhibition in Neocortical Circuits. Biological Psychiatry, 2017, 81, 821-831.	0.7	135
683	Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia. Molecular Psychiatry, 2017, 22, 4-12.	4.1	94

#	Article	IF	Citations
684	Investigating Cortical Inhibition in First-Degree Relatives and Probands in Schizophrenia. Scientific Reports, 2017, 7, 43629.	1.6	17
685	GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies. Frontiers in Psychiatry, 2017, 8, 118.	1.3	119
686	Theranostic Biomarkers for Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 733.	1.8	78
687	Dysbindin Deficiency Modifies the Expression of GABA Neuron and Ion Permeation Transcripts in the Developing Hippocampus. Frontiers in Genetics, 2017, 8, 28.	1.1	21
688	Modeling Schizophrenia in Animals. , 2017, , 587-617.		0
689	Epigenetic biomarkers in neuropsychiatric disorders. , 2017, , 35-66.		2
690	Mapping pathologic circuitry in schizophrenia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 389-417.	1.0	44
691	Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior. Cell Research, 2018, 28, 221-248.	5.7	78
692	Attenuated resting-state functional connectivity in patients with childhood- and adult-onset schizophrenia. Schizophrenia Research, 2018, 197, 219-225.	1.1	22
693	Efficient Generation of CA3 Neurons from Human Pluripotent Stem Cells Enables Modeling of Hippocampal Connectivity InÂVitro. Cell Stem Cell, 2018, 22, 684-697.e9.	5.2	118
694	Toward Better Strategies for Understanding Disrupted Cortical Excitatory/Inhibitory Balance in Schizophrenia. Biological Psychiatry, 2018, 83, 632-634.	0.7	3
695	Deletion of dopamine D ₂ receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3476-3481.	3.3	29
696	GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia. Molecular Psychiatry, 2018, 23, 1496-1505.	4.1	52
697	The Subventricular Zone: A Key Player in Human Neocortical Development. Neuroscientist, 2018, 24, 156-170.	2.6	25
698	HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophreniaâ€like animals. Journal of Cellular Physiology, 2018, 233, 530-548.	2.0	61
699	DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 38-49.	2.5	67
700	Neurodevelopmental disease mechanisms, primary cilia, and endosomes converge on the BLOCâ€1 and BORC complexes. Developmental Neurobiology, 2018, 78, 311-330.	1.5	21
701	Prefrontal and Striatal Gamma-Aminobutyric AcidÂLevels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients. Biological Psychiatry, 2018, 83, 475-483.	0.7	66

#	Article	IF	Citations
702	Short-Term Exposure to Enriched Environment in Adult Rats Restores MK-801-Induced Cognitive Deficits and GABAergic Interneuron Immunoreactivity Loss. Molecular Neurobiology, 2018, 55, 26-41.	1.9	24
703	Tet1 overexpression leads to anxietyâ€like behavior and enhanced fear memoriesviathe activation of calciumâ€dependent cascade through Egr1 expression in mice. FASEB Journal, 2018, 32, 390-403.	0.2	18
704	Altered Gradients of Glutamate and Gamma-Aminobutyric Acid Transcripts in the Cortical Visuospatial Working Memory Network in Schizophrenia. Biological Psychiatry, 2018, 83, 670-679.	0.7	47
705	In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study. Schizophrenia Research, 2018, 193, 295-303.	1.1	44
706	A CRITICAL REVIEW ON HYPOTHESIS, PATHOPHYSIOLOGY OF SCHIZOPHRENIA, AND ROLE OF VITAMINS IN ITS MANAGEMENT. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 25.	0.3	0
707	Alterations of GABAergic Neuron-Associated Extracellular Matrix and Synaptic Responses in Gad1-Heterozygous Mice Subjected to Prenatal Stress. Frontiers in Cellular Neuroscience, 2018, 12, 284.	1.8	31
708	Chromosomal Conformations and Epigenomic Regulation in Schizophrenia. Progress in Molecular Biology and Translational Science, 2018, 157, 21-40.	0.9	16
709	The Perineuronal â€˜Safetyâ€™ Net? Perineuronal Net Abnormalities in Neurological Disorders. Frontiers in Molecular Neuroscience, 2018, 11, 270.	1.4	125
710	Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiology of Disease, 2019, 131, 104208.	2.1	203
711	Positron emission tomography imaging of the Î³-aminobutyric acid system. Neuroscience Letters, 2019, 691, 35-43.	1.0	22
712	White matter neuron biology and neuropathology in schizophrenia. NPJ Schizophrenia, 2019, 5, 10.	2.0	24
713	Biological Psychiatry and Psychopharmacology. , 2019, , 397-458.		0
714	Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders. International Journal of Molecular Sciences, 2019, 20, 3207.	1.8	24
715	Reduced cortical somatostatin gene expression in a rat model of maternal immune activation. Psychiatry Research, 2019, 282, 112621.	1.7	8
716	The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. BMC Psychiatry, 2019, 19, 314.	1.1	5
717	Ketamine-Treatment During Late Adolescence Impairs Inhibitory Synaptic Transmission in the Prefrontal Cortex and Working Memory in Adult Rats. Frontiers in Cellular Neuroscience, 2019, 13, 372.	1.8	12
718	Reduced expression of synapsin II in a chronic phencyclidine preclinical rat model of schizophrenia. Synapse, 2019, 73, e22084.	0.6	1
719	Effect of pre- and post-treatment with Bacopa monnieri (Brahmi) on phencyclidine-induced disruptions in object recognition memory and cerebral calbindin, parvalbumin, and calretinin immunoreactivity in rats . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1103-1117.	1.0	9

#	Article	IF	Citations
720	The Current and Future Potential of Transcranial Magnetic Stimulation With Electroencephalography in Psychiatry. Clinical Pharmacology and Therapeutics, 2019, 106, 734-746.	2.3	35
721	Molecular programs underlying differences in the expression of mood disorders in males and females. Brain Research, 2019, 1719, 89-103.	1.1	7
722	Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder. Translational Psychiatry, 2019, 9, 151.	2.4	127
723	Neurons and glial cells in bipolar disorder: A systematic review of postmortem brain studies of cell number and size. Neuroscience and Biobehavioral Reviews, 2019, 103, 150-162.	2.9	15
724	The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis. Schizophrenia Bulletin, 2019, 45, 1170-1183.	2.3	44
725	Cerebellar GABAergic correlates of cognitionâ€mediated verbal fluency in physiology and schizophrenia. Acta Psychiatrica Scandinavica, 2019, 139, 582-594.	2.2	16
726	Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine. Translational Psychiatry, 2019, 9, 321.	2.4	45
727	Aging and Central Auditory Disinhibition: Is It a Reflection of Homeostatic Downregulation or Metabolic Vulnerability?. Brain Sciences, 2019, 9, 351.	1.1	17
728	Yoga: Balancing the excitation-inhibition equilibrium in psychiatric disorders. Progress in Brain Research, 2019, 244, 387-413.	0.9	7
729	Disinhibition of the prefrontal cortex leads to brain-wide increases in neuronal activation that are modified by spatial learning. Brain Structure and Function, 2019, 224, 171-190.	1.2	5
730	Expression of Transcripts Selective for GABA Neuron Subpopulations across the Cortical Visuospatial Working Memory Network in the Healthy State and Schizophrenia. Cerebral Cortex, 2019, 29, 3540-3550.	1.6	36
731	Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism. Neurochemical Research, 2019, 44, 102-116.	1.6	44
732	Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 633-642.	2.3	23
733	Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. Biological Psychiatry, 2020, 87, 204-214.	0.7	53
734	Amelioration of cognitive impairments induced by GABA hypofunction in the male rat prefrontal cortex by direct and indirect dopamine D1 agonists SKF-81297 and d-Govadine. Neuropharmacology, 2020, 162, 107844.	2.0	9
735	Reduced inÂvivo visual cortex GABA in schizophrenia, a replication in a recent onset sample. Schizophrenia Research, 2020, 215, 217-222.	1.1	18
736	Glutamate dehydrogenase deficiency disrupts glutamate homeostasis in hippocampus and prefrontal cortex and impairs recognition memory. Genes, Brain and Behavior, 2020, 19, e12636.	1.1	13
737	Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics. Neuropsychopharmacology, 2020, 45, 656-665.	2.8	49

#	Article	IF	Citations
738	Effects of (+)-bicuculline, a GABAa receptor antagonist, on auditory steady state response in free-moving rats. PLoS ONE, 2020, 15, e0236363.	1.1	7
739	Neuromorphological Aspects of the GABAergic Hypothesis of the Pathogenesis of Schizophrenia. Neuroscience and Behavioral Physiology, 2020, 50, 663-668.	0.2	0
740	Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain. European Neuropsychopharmacology, 2020, 41, 106-117.	0.3	12
741	Microbiome and Schizophrenia: Current Evidence and Future Challenges. Current Behavioral Neuroscience Reports, 2020, 7, 51-61.	0.6	9
742	Î”-9-Tetrahydrocannabinol treatment during adolescence and alterations in the inhibitory networks of the adult prefrontal cortex in mice subjected to perinatal NMDA receptor antagonist injection and to postweaning social isolation. Translational Psychiatry, 2020, 10, 177.	2.4	14
743	The polygenic architecture of schizophrenia â€" rethinking pathogenesis and nosology. Nature Reviews Neurology, 2020, 16, 366-379.	4.9	122
744	Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development. Biomarkers in Neuropsychiatry, 2020, 3, 100015.	0.7	22
745	Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Schizophrenia Research, 2020, 222, 122-132.	1.1	27
746	Developmental alterations in the transcriptome of three distinct rodent models of schizophrenia. PLoS ONE, 2020, 15, e0232200.	1.1	9
747	GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons. PLoS ONE, 2020, 15, e0233895.	1.1	25
748	Frequency-dependent gating of feedforward inhibition in thalamofrontal synapses. Molecular Brain, 2020, 13, 68.	1.3	0
749	Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems. Brain Structure and Function, 2020, 225, 1719-1742.	1.2	7
750	Transcriptomic Landscape and Functional Characterization of Induced Pluripotent Stem Cellâ€"Derived Cerebral Organoids in Schizophrenia. JAMA Psychiatry, 2020, 77, 745.	6.0	102
751	Neurochemical models of psychosis risk and onset. , 2020, , 229-247.		0
752	Binding of clozapine to the GABAB receptor: clinical and structural insights. Molecular Psychiatry, 2020, 25, 1910-1919.	4.1	52
753	Transcriptional and imaging-genetic association of cortical interneurons, brain function, and schizophrenia risk. Nature Communications, 2020, 11, 2889.	5.8	59
754	Analysis of global gene expression at seven brain regions of patients with schizophrenia. Schizophrenia Research, 2020, 223, 119-127.	1.1	6
755	Stem Cells for Improving the Treatment of Neurodevelopmental Disorders. Stem Cells and Development, 2020, 29, 1118-1130.	1.1	7

#	Article	IF	Citations
756	ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. Journal of Neuroscience Methods, 2020, 334, 108548.	1.3	30
757	Frontal GABA in schizophrenia: A meta-analysis of ¹H-MRS studies. World Journal of Biological Psychiatry, 2021, 22, 1-13.	1.3	29
758	Oscillotherapeutics â€“ Time-targeted interventions in epilepsy and beyond. Neuroscience Research, 2020, 152, 87-107.	1.0	45
759	Dysregulation of Epigenetic Control Contributes to Schizophrenia-Like Behavior in Ebp1+/â^’ Mice. International Journal of Molecular Sciences, 2020, 21, 2609.	1.8	2
760	Subclass imbalance of parvalbumin-expressing GABAergic neurons in the hippocampus of a mouse ketamine model for schizophrenia, with reference to perineuronal nets. Schizophrenia Research, 2021, 229, 80-93.	1.1	10
761	Distinct Laminar and Cellular Patterns of GABA Neuron Transcript Expression in Monkey Prefrontal and Visual Cortices. Cerebral Cortex, 2021, 31, 2345-2363.	1.6	11
762	Links Between Human and Animal Models of Trauma and Psychosis: A Narrative Review. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 154-165.	1.1	1
763	Dysregulation of the unfolded protein response (UPR) in the dorsolateral prefrontal cortex in elderly patients with schizophrenia. Molecular Psychiatry, 2021, 26, 1321-1331.	4.1	27
764	The epigenetics of suicide: The critical impact of environment on epigenetic regulation in suicide. , 2021, , 393-427.		1
765	Frontal Cortex. , 2021, , 27-61.		0
766	Endocannabinoid system in the neurodevelopment of GABAergic interneurons: implications for neurological and psychiatric disorders. Reviews in the Neurosciences, 2021, 32, 803-831.	1.4	5
767	An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data. Molecular Psychiatry, 2022, 27, 95-112.	4.1	19
768	The Aging GABAergic System and Its Nutritional Support. Journal of Nutrition and Metabolism, 2021, 2021, 1-17.	0.7	6
769	Weak Association Between the Glutamate Decarboxylase 1 Gene (GAD1) and Schizophrenia in Han Chinese Population. Frontiers in Neuroscience, 2021, 15, 677153.	1.4	0
770	Reduced cortical GABA and glutamate in high schizotypy. Psychopharmacology, 2021, 238, 2459-2470.	1.5	6
771	Maternal Deprivation in Rats Decreases the Expression of Interneuron Markers in the Neocortex and Hippocampus. Frontiers in Neuroanatomy, 2021, 15, 670766.	0.9	10
772	Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype. Frontiers in Cell and Developmental Biology, 2021, 9, 693919.	1.8	4
773	Altered interhemispheric signal propagation in schizophrenia and depression. Clinical Neurophysiology, 2021, 132, 1604-1611.	0.7	5

#	Article	IF	Citations
774	Research Progress on the Correlation Between Epigenetics and Schizophrenia. Frontiers in Neuroscience, 2021, 15, 688727.	1.4	6
775	Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia. Neuropsychopharmacology, 2022, 47, 292-308.	2.8	84
776	Current findings and perspectives on aberrant neural oscillations in schizophrenia. Psychiatry and Clinical Neurosciences, 2021, 75, 358-368.	1.0	46
777	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Molecular Psychiatry, 2022, 27, 744-757.	4.1	60
778	Developmental dysregulation of excitatory-to-inhibitory GABA-polarity switch may underlie schizophrenia pathology: A monozygotic-twin discordant case analysis in human iPS cell-derived neurons. Neurochemistry International, 2021, 150, 105179.	1.9	9
779	Cortical Abnormalities in Schizophrenia Identified by Structural Magnetic Resonance Imaging. Archives of General Psychiatry, 1999, 56, 537-547.	13.8	345
781	The Neurochemistry of Schizophrenia. , 0, , 349-364.		4
783	Animal Models of Schizophrenia. , 0, , 388-402.		5
785	Contributions of the Neocortical Svz to Human Brain Development. , 2006, , 117-158.		1
786	Auditory Cortex Anatomy and Asymmetry in Schizophrenia. , 2009, , 353-381.		3
787	Co-Regulation and Epigenetic Dysregulation in Schizophrenia and Bipolar Disorder. , 2012, , 281-347.		3
788	The Role of the Gadd45 Family in the Nervous System: A Focus on Neurodevelopment, Neuronal Injury, and Cognitive Neuroepigenetics. Advances in Experimental Medicine and Biology, 2013, 793, 81-119.	0.8	52
789	Summary of Prefrontal Molecular Abnormalities in the Stanley Foundation Neuropathology Consortium. Neurobiological Foundation of Aberrant Behaviors, 2002, , 105-137.	0.2	2
790	Viral Mechanisms of Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2000, , 79-102.	0.2	3
791	Dysregulation of Glutathione Synthesis in Psychiatric Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 269-297.	0.4	6
792	5-HT6 Receptors as Targets for the Treatment of Cognitive Deficits in Schizophrenia. Receptors, 2006, , 495-515.	0.2	5
793	Function of GABAB and Ï•Containing GABAA Receptors (GABAC Receptors) in the Regulation of Basic and Higher Integrated Sleep-Waking Processes. , 2010, , 169-188.		3
794	Nicotinic Receptors and Functional Regulation of GABA Cell Microcircuitry in Bipolar Disorder and Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 401-417.	0.9	13

#	Article	IF	Citations
795	Functions of GABAA-Receptors: Pharmacology and Pathophysiology. Handbook of Experimental Pharmacology, 2001, , 101-116.	0.9	18
796	Developmental Consequences of Prenatal Exposure to Maternal Immune Activation. , 2011, , 263-285.		1
797	Chemical Neurotransmission. , 2008, , 59-123.		1
798	Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers. , 0, .		1
799	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. , 0, .		1
800	Signal Transmission, Rather Than Reception, is the Underlying Neurochemical Abnormality in Schizophrenia. , 0, .		8
801	Colocalization of integrin receptors and reelin in dendritic spine postsynaptic densities of adult nonhuman primate cortex. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3550-5.	3.3	117
803	Neurobiology of schizophrenia. Current Opinion in Psychiatry, 1996, 9, 50-56.	3.1	54
804	Tiagabine, a Specific Î³-Aminobutyric Acid Transporter-1 Inhibitor, in the Treatment of Psychosis. Journal of Clinical Psychopharmacology, 2001, 21, 347-349.	0.7	3
806	Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. Journal of Clinical Investigation, 2009, 119, 706-716.	3.9	202
807	Alterations in Chandelier Neuron Axon Terminals in the Prefrontal Cortex of Schizophrenic Subjects. American Journal of Psychiatry, 1999, 156, 1709-1719.	4.0	234
808	Alterations of perineuronal nets in the dorsolateral prefrontal cortex of neuropsychiatric patients. International Journal of Bipolar Disorders, 2019, 7, 24.	0.8	33
809	- Brain-Derived Neurotrophic Factor in Suicide Pathophysiology. , 2012, , 166-185.		10
810	Epigenetic Effects of Childhood Adversity in the Brain and Suicide Risk. , 2012, , 302-323.		3
811	A Review of Glutamate Receptors II: Pathophysiology and Pathology. Journal of Toxicologic Pathology, 2008, 21, 133-173.	0.3	15
812	Potential microbial origins of schizophrenia and their treatments. Drugs of Today, 2009, 45, 305.	0.7	5
813	GAD1 mRNA Expression and DNA Methylation in Prefrontal Cortex of Subjects with Schizophrenia. PLoS ONE, 2007, 2, e809.	1.1	192
814	The Effect of Repetitive Transcranial Magnetic Stimulation on Gamma Oscillatory Activity in Schizophrenia. PLoS ONE, 2011, 6, e22627.	1.1	72

#	Article	IF	Citations
815	Neuropathological Similarities and Differences between Schizophrenia and Bipolar Disorder: A Flow Cytometric Postmortem Brain Study. PLoS ONE, 2012, 7, e33019.	1.1	27
816	Induction of the GABA Cell Phenotype: An In Vitro Model for Studying Neurodevelopmental Disorders. PLoS ONE, 2012, 7, e33352.	1.1	21
817	Fgfr1 Inactivation in the Mouse Telencephalon Results in Impaired Maturation of Interneurons Expressing Parvalbumin. PLoS ONE, 2014, 9, e103696.	1.1	19
818	GAD1 Gene Expression in Blood of Patients with First-Episode Psychosis. PLoS ONE, 2017, 12, e0170805.	1.1	5
819	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. Journal of Psychiatry and Neuroscience, 2019, 44, 111-119.	1.4	26
820	Low levels of muscarinic M1 receptorâ€“positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. Journal of Psychiatry and Neuroscience, 2018, 43, 338-346.	1.4	30
821	Early Social Isolation Stress and Perinatal NMDA Receptor Antagonist Treatment Induce Changes in the Structure and Neurochemistry of Inhibitory Neurons of the Adult Amygdala and Prefrontal Cortex. ENeuro, 2017, 4, ENEURO.0034-17.2017.	0.9	58
822	Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders. Current Molecular Medicine, 2015, 15, 146-167.	0.6	404
823	Neural models of schizophrenia. Dialogues in Clinical Neuroscience, 2000, 2, 267-279.	1.8	10
824	Neonatal disconnection of the rat hippocampus: a neurodevelopmental model of schizophrenia. Dialogues in Clinical Neuroscience, 2002, 4, 361-367.	1.8	5
825	Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia. Dialogues in Clinical Neuroscience, 2009, 11, 269-280.	1.8	37
826	DNA methylation and demethylation as targets for antipsychotic therapy. Dialogues in Clinical Neuroscience, 2014, 16, 419-429.	1.8	62
827	Epigenetic mechanisms in schizophrenia. Dialogues in Clinical Neuroscience, 2014, 16, 405-417.	1.8	74
828	Use of the epigenetic toolbox to contextualize common variants associated with schizophrenia risk. Dialogues in Clinical Neuroscience, 2019, 21, 407-416.	1.8	3
829	Time Windows of Interneuron Development: Implications to Our Understanding of the Aetiology and Treatment of Schizophrenia. AIMS Neuroscience, 2015, 2, 294-321.	1.0	2
830	Gamma Oscillation in Schizophrenia. Psychiatry Investigation, 2011, 8, 288.	0.7	45
831	GABAergic Gene Regulatory Elements Used in Adeno-Associated Viral Vectors. Frontiers in Neurology, 2021, 12, 745159.	1.1	4
833	Early Disruption of Corticolimbic Circuitry as a Model of Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2000, , 259-274.	0.2	1

#	Article	IF	Citations
834	Modulation of Cellular Signaling Pathways by Antipsychotic Drugs. Handbooks of Pharmacology and Toxicology, 2000, , 199-219.	0.1	0
835	Post Mortem Studies of the Hippocampal Formation in Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2002, , 253-266.	0.2	0
836	In Situ/Histological Approaches to Neurotransmitter-Specific Postmortem Brain Studies of Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2002, , 173-210.	0.2	0
837	Microanatomical Findings in Postmortem Brain Tissue from Subjects with Schizophrenia: Disturbances in Thalamocortical and Corticocortical Connectivity in Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2002, , 151-171.	0.2	0
838	Dorsolateral Prefrontal Cortical Parallel Circuit in Schizophrenia: Postmortem Abnormalities. Neurobiological Foundation of Aberrant Behaviors, 2002, , 235-251.	0.2	0
839	Defining the Role of Specific Limbic Circuitry in the Pathophysiology of Schizophrenia and Bipolar Disorder. Neurobiological Foundation of Aberrant Behaviors, 2002, , 211-233.	0.2	0
840	Analysis of Brain Disorders Using DNA Microarrays. Research and Perspectives in Neurosciences, 2003, , 45-63.	0.4	0
841	Molecular Neurotoxicology of 6-Hydroxydopamine and Methamphetamine. , 2003, , .		0
843	Neurodegenerative models of schizophrenia. , 2004, , 373-389.		1
844	Transcriptomes in schizophrenia: assessing altered gene expression with microarrays. , 2004, , 210-223.		0
845	Development of thalamocortical circuitry and the pathophysiology of schizophrenia. , 2004, , 310-329.		0
846	Dopamine and Schizophrenia. , 2005, , 153-168.		0
847	Cortical Development and Neuropathology in Schizophrenia. Novartis Foundation Symposium, 1995, 193, 277-295.	1.2	13
848	Reelin Downregulation as a Prospective Treatment Target for GABAergic Dysfunction in Schizophrenia. , 2008, , 341-363.		1
849	Magnetic Resonance Spectroscopy. , 2009, , 403-442.		0
850	Brain abnormalities in schizophrenia. , 2009, , 101-118.		0
851	Disinhibition of Prefrontal Cortex Neurons in Schizophrenia. , 2010, , 99-111.		1
852	Recombinant Human Erythropoietin: Novel Approach to Neuroprotection and Neuroregeneration in Schizophrenia. , 2010, , 397-415.		0

#	Article	IF	Citations
853	New Antiepileptic Drugs in Neuropsychiatric Disorders â€“ Basic Mechanisms Related to Clinical Efficacy. , 2010, , 485-504.		2
854	Gap Junctions and the Notion of Electrical Coupling Between Axons. , 2010, , 212-243.		0
855	Cerebellar Ataxia. , 2010, , 152-177.		0
857	Epileptiform Discharges In Vitro. , 2010, , 302-312.		0
859	Cortical Neurons and Their Models. , 2010, , 179-211.		0
861	Persistent Gamma Oscillations. , 2010, , 282-301.		0
862	Very Fast Oscillations. , 2010, , 245-268.		0
865	Historical Prelude. , 2010, , 16-30.		0
866	Beta-2 Oscillations. , 2010, , 269-281.		0
867	Overview of In Vivo Cortical Oscillations. , 2010, , 31-69.		0
868	Epigenetic Regulation of GABAergic Targets in Psychiatry. , 2011, , 23-40.		0
870	Schizophrenie. , 2012, , 437-496.		0
872	Epigenetic Therapies in Neurological Diseases. Epigenetics and Human Health, 2013, , 167-193.	0.2	0
875	The relation of the change in symptoms and cognitive functions with the change in cortical inhibition parameters measured by transcranial magnetic stimulation: An eight-week follow-up study. Turk Psikiyatri Dergisi, 2014, , .	0.2	2
876	Pathophysiology of Schizophrenia. , 2014, , 35-57.		0
877	Factores Extracelulares de la Actividad del Receptor de Glutamato N-metil-D-Aspartato (Nmda) en Esquizofrenia. Anales De La Facultad De Medicina, 2014, 60, 265.	0.0	0
878	In Pursuit of the Molecular Neuropathology of Schizophrenia-Reply. Archives of General Psychiatry, 1995, 52, 277.	13.8	0
879	Neuroscience and the future of psychiatry. Current Opinion in Psychiatry, 1998, 12, 633-636.	3.1	0

#	Article	IF	Citations
880	Outstanding Issues in Neuropathology and Neurochemistry of Schizophrenia. , 1999, , 279-290.		0
882	Neuropathologies of Schizophrenia. , 1999, , 221-234.		0
886	Histone and DNA Methylome in Neurodegenerative, Neuropsychiatric and Neurodevelopmental Disorders. RNA Technologies, 2019, , 63-102.	0.2	1
888	Postnatal Development of Glutamate and GABA Transcript Expression in Monkey Visual, Parietal, and Prefrontal Cortices. Cerebral Cortex, 2021, 31, 2026-2037.	1.6	5
891	Toxoplasma gondii infection damages the perineuronal nets in a murine model. Memorias Do Instituto Oswaldo Cruz, 2020, 115, e200007.	0.8	6
892	Animal models of schizophrenia: a critical review. Journal of Psychiatry and Neuroscience, 2001, 26, 395-410.	1.4	110
893	Schizophrenia: neural mechanisms for novel therapies. Molecular Medicine, 2003, 9, 3-9.	1.9	25
897	Elevated glutamate, glutamine and GABA levels and reduced taurine level in a schizophrenia model using an in vitro proton nuclear magnetic resonance method. American Journal of Translational Research (discontinued), 2019, 11, 5919-5931.	0.0	2
898	A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia. Molecular Biology Reports, 2022, 49, 2015-2024.	1.0	10
899	Lamotrigine-Associated Movement Disorder: A Literature Review. Neurology India, 2021, 69, 1524.	0.2	9
900	SLC6A1 and Neuropsychiatric Diseases: The Role of Mutations and Prospects for Treatment with Genome Editing Systems. Neurochemical Journal, 2021, 15, 376-389.	0.2	0
901	The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression. Frontiers in Psychiatry, 2021, 12, 716600.	1.3	0
903	Cognitive Dysfunction and Prefrontal Cortical Circuit Alterations in Schizophrenia: Developmental Trajectories. Biological Psychiatry, 2022, 92, 450-459.	0.7	34
904	Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia. American Journal of Psychiatry, 2022, 179, 277-287.	4.0	19
907	Alterations in Cortical GABA Neurotransmission in Schizophrenia: Causes and Consequences. , 0, , 205-218.		0
913	At-risk mental states: possible clinical and theoretical developments. Rivista Di Psichiatria, 2012, 47, 73-5.	0.6	2
914	Gadd45 in Neuronal Development, Function, and Injury. Advances in Experimental Medicine and Biology, 2022, 1360, 117-148.	0.8	2
915	Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
916	Targeting Î±6GABAA receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal models. Biomedicine and Pharmacotherapy, 2022, 150, 113022.	2.5	5
917	Multiparameter Optimization of Naphthyridine Derivatives as Selective Î±5-GABA_A Receptor Negative Allosteric Modulators. Journal of Medicinal Chemistry, 2022, 65, 7876-7895.	2.9	4
919	Clozapineâ€™s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. , 2022, 236, 108236.		19
924	Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. Biological Psychiatry, 2023, 93, 125-136.	0.7	12
925	Decreased activation of parvalbumin interneurons in the medial prefrontal cortex in intact inbred Roman rats with schizophrenia-like reduced sensorimotor gating. Behavioural Brain Research, 2023, 437, 114113.	1.2	3
926	Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. , 2023, 241, 108279.		17
927	Layer III pyramidal cells in the prefrontal cortex reveal morphological changes in subjects with depression, schizophrenia, and suicide. Translational Psychiatry, 2022, 12, .	2.4	4
928	Disrupted-in-schizophrenia-1 is required for normal pyramidal cellâ€“interneuron communication and assembly dynamics in the prefrontal cortex. ELife, 0, 11, .	2.8	4
931	NRG1 knockdown rescues PV interneuron GABAergic maturation deficits and schizophrenia behaviors in fetal growth restriction mice. Cell Death Discovery, 2022, 8, .	2.0	2
932	Laminar-Specific Alterations in Calbindin-Positive Boutons in the Prefrontal Cortex of Subjects With Schizophrenia. Biological Psychiatry, 2023, 94, 142-152.	0.7	0
933	Chronic haloperidol administration downregulates select BDNF transcript and protein levels in the dorsolateral prefrontal cortex of rhesus monkeys. Frontiers in Psychiatry, 0, 14, .	1.3	0
934	Distinctive effects of NMDA receptor modulators on cerebral microcirculation in a schizophrenia mouse model. Biochemical and Biophysical Research Communications, 2023, 653, 62-68.	1.0	0
935	Canonical and Non-Canonical Antipsychoticsâ€™ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia. International Journal of Molecular Sciences, 2023, 24, 5945.	1.8	2
936	Neurotransmission-related gene expression in the frontal pole is altered in subjects with bipolar disorder and schizophrenia. Translational Psychiatry, 2023, 13, .	2.4	1
937	Localization and Diagnostic Specificity of Glutamic Acid Decarboxylase Transcript Alterations in the Dorsolateral Prefrontal Cortex in Schizophrenia. Biological Psychiatry, 2023, 94, 322-331.	0.7	2
938	Regulation of the E/I-balance by the neural matrisome. Frontiers in Molecular Neuroscience, 0, 16, .	1.4	3
939	The Nature of Prefrontal Cortical GABA Neuron Alterations in Schizophrenia: Markedly Lower Somatostatin and Parvalbumin Gene Expression Without Missing Neurons. American Journal of Psychiatry, 2023, 180, 495-507.	4.0	15